    		                		            		                                                                                                                                          	    		   		   	  	       	            							    	    																																			    																	    	    	                             		       	                                                                                                   	        						    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               	            			        	                            						    	    																																			    																	    	    	                             		       	                                                                                                                                                                                                                                                                               	     <!DOCTYPE html><html><head>        	<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />    <meta charset="utf-8" />        	<title>DailyMed - ABILIFY MAINTENA- aripiprazole    </title>                <!--[if lt IE 9]>        <script src="//html5shim.googlecode.com/svn/trunk/html5.js"></script>    <![endif]-->    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/skeleton.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/jquery.jqzoom.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/style.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/header-search.min.css" />    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive.min.css" />    <link rel="stylesheet" type="text/css" media="print" href="dailymed/css/print.min.css" />    <!--[if !IE]><!-->    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive-tables.min.css" />    <!--<![endif]-->    <link rel="icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon" />    <link rel="shortcut icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon"/>        <link rel="apple-touch-icon" sizes="57x57" href="dailymed/images/favicons/apple-touch-icon-57x57.png">    <link rel="apple-touch-icon" sizes="114x114" href="dailymed/images/favicons/apple-touch-icon-114x114.png">    <link rel="apple-touch-icon" sizes="72x72" href="dailymed/images/favicons/apple-touch-icon-72x72.png">    <link rel="apple-touch-icon" sizes="144x144" href="dailymed/images/favicons/apple-touch-icon-144x144.png">    <link rel="apple-touch-icon" sizes="60x60" href="dailymed/images/favicons/apple-touch-icon-60x60.png">    <link rel="apple-touch-icon" sizes="120x120" href="dailymed/images/favicons/apple-touch-icon-120x120.png">    <link rel="apple-touch-icon" sizes="76x76" href="dailymed/images/favicons/apple-touch-icon-76x76.png">    <link rel="apple-touch-icon" sizes="152x152" href="dailymed/images/favicons/apple-touch-icon-152x152.png">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-196x196.png" sizes="196x196">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-160x160.png" sizes="160x160">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-96x96.png" sizes="96x96">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-16x16.png" sizes="16x16">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-32x32.png" sizes="32x32">    <meta name="msapplication-config" content="/dailymed/images/favicons/browserconfig.xml" />    <meta name="msapplication-TileColor" content="#da532c">    <meta name="msapplication-TileImage" content="/dailymed/images/favicons/mstile-144x144.png">    <meta name="description" content="" />    <meta name="keywords" content="" />     <meta name="robots" content="noimageindex, noodp, noydir" />     <meta name="viewport" id="viewport" content="width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0" />    <script src="/dailymed/scripts/modernizr-2.0.6.min.js"></script>        <script type="text/javascript" src="//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>        <script type="text/javascript">        if (typeof jQuery == 'undefined')        {              document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');        }    </script>                	                	            	    	<script type="text/javascript">		var basepath = "/dailymed";;		var availableClasses =  new Array();;		for(var i = 0; i < availableClasses.length; i++){			availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();		}		var labeltitle = "ABILIFY MAINTENA- aripiprazole   <br>";;		var emailLink = "";;		var emailrequest = "0";;	</script>    <script src="/dailymed/scripts/javascript-html-attribute-encoding.min.js"></script>	<script src="/dailymed/scripts/scripts.min.js"></script>        <script type='text/javascript' src="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js"></script>    <script type="text/javascript">        if (typeof jQuery.ui == 'undefined')        {            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="dailymed/css/jquery-ui-1.10.4.custom.min.css">');        }        else{            document.write('<link rel="stylesheet" href="/ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');        }    </script>    <script type='text/javascript' src='/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'></script>      <script type="text/javascript" src="/dailymed/scripts/jquery.placeholder.min.js"></script>    <script src="//www.accessdata.fda.gov/spl/stylesheet/spl.js" type="text/javascript" charset="utf-8">/* */</script>    <!-- Magnific Popup core CSS file -->    <link rel="stylesheet" href="dailymed/css/magnific-popup.min.css">        <!-- Magnific Popup core JS file -->    <script src="/dailymed/scripts/jquery.magnific-popup.js"></script>        <meta name = "format-detection" content = "telephone=no"></head><body class="inner drug-info">	<div class="container_1000 bg_shadow">        <div style="width: 0; height: 0;"><a href="#" id="top-of-page"></a></div><header>	<div class="topHeader">				<ul id="skip">		<li><a href="#skip-main-content">Skip to Main Content</a></li></ul>		<nav class="topHeaderNav">        	<div class="topNIHLogo mobileview">        		<a href="http://www.nih.gov" class="top-logo" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>            	<a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>			<div class="container">				<div class="sixteen columns">                	<div class="topNIHLogo"><a href="http://www.nih.gov" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>                    <a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>					<ul>																		<li class="safety"><a title="Report Adverse Events" href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events </a><span>|</span><a title="FDA Safety Reporting and Recalls" href="http://www.fda.gov/Safety/Recalls" target="_blank">Recalls</a></li>					</ul>				</div>			</div>		</nav>		<div class="divider"></div>	</div>	<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png" alt="DailyMed" /></div>	<div class="bottomHeader">		<div class="header-image">						<div class="mobile-menu-btn closed hasjs" tabindex="0"></div><div class="mobile-menu">		<div class="mobile-menu-container">		<div class="pro-menu active">			<div class="first half">				<ul>					<li><a href="dailymed/index.cfm">Home</a></li>					<li>						News						<ul>							<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>							<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>						</ul>					</li>					<li><a href="dailymed/about-dailymed.cfm">About Dailymed</a></li>					<li><a href="dailymed/contact-us.cfm">Contact Us</a></li>					<li>						Safety Reporting &amp; Recalls						<ul>							<li><a href="/www.accessdata.fda.gov/scripts/medwatch/">Report Adverse Events</a></li>							<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey Recalls</a></li>						</ul>					</li>					<li>						<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>											</li>				</ul>			</div>			<div class="last half">				<ul>					<li>						NLM SPL Resources						<ul>							<li>								<a href="dailymed/spl-resources.cfm">Download Data</a>								<ul>									<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>									<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>									<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>								</ul>							</li>							<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>							<li><a href="dailymed/spl-resources-all-mapping-files.cfm">Articles &amp; Presentations</a></li>						</ul>					</li>					<li>						Application Development Support						<ul>							<li>								<a href="dailymed/app-support.cfm">Resources</a>								<ul>									<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																		<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>								</ul>							</li>						</ul>					</li>					<li><a href="dailymed/help.cfm">Help</a></li>				</ul>			</div>		</div>			</div></div>			<a href="dailymed/index.cfm" class="logo" title="DailyMed">DailyMed</a>						<div class="header-search-container">				<div id="header-search">									    					    				    <form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all" value="all" />					<label for="labeltype-all">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human" value="human"/>					<label for="labeltype-human">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden" name="labeltype" id="labeltype-animal" value="animal" />					<label for="labeltype-animal">Animal Drugs</label>							</li>							<li class="more-ways" id="header-search-more-ways">					<a href="#" id="more-ways-button" class="more-ways-label">More ways to search</a>					<ul id="more-ways-dropdown" class="dropdown" style="display:none;">						<li>							<a href="dailymed/advanced-search.cfm">Advanced Search</a>						</li>						<li>							<a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a>						</li>						<li>							<a href="dailymed/archives/index.cfm">Label Archives</a>						</li>						<li>							<a class="external-link" href="http://pillbox.nlm.nih.gov" target="_blank">Tablet/Capsule ID Tool</a>						</li>					</ul>				</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">									<button class="search-button">  </button>							</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>									</div>			</div>			<div class="mobile-search-btn" tabindex="0"></div>												<div class="header-bg">																										</div>			<div class="divider"></div>		</div>		<div class="bottomHeaderContent">									<div class="search mobile-search">				<div class="divider_10 nomargin mobileview"></div>				<div class="searchTool mobileview"></div>															<form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all-2" value="all" />					<label for="labeltype-all-2">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human-2" value="human"/>					<label for="labeltype-human-2">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden"  name="labeltype" id="labeltype-animal-2" value="animal" />					<label for="labeltype-animal-2">Animal Drugs</label>							</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchToolsQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">			</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>								<div class="divider"></div>								<nav class="bottomHeaderNav">                <noscript>                <div class="tabletnav no-js">                    <div class="col">                        <ul>                            <li><a href="dailymed/index.cfm">Home</a></li>                            <li>News                                <ul>                                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                                    <li><a href="dailymed/rss-updates.cfm">Get RSS News & Updates</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Search                                <ul>                                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>                                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                                        <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                            <li>NLM SPL Resources                                <ul>                                    <li><a href="dailymed/spl-resources.cfm">Download Data</a>                                        <ul>                                            <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                            <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                            <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                                        </ul>                                    </li>                                    <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                                    <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Application Development Support                                <ul>                                    <li><a href="dailymed/app-support.cfm">Resources</a>                                        <ul>                                            <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                            <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                                        </ul>                                    </li>                                </ul>                            </li>                            <li><a href="dailymed/help.cfm">Help</a></li>                        </ul>                    </div>                </div>           		</noscript>                					<ul class="webview hasjs">						<li><a href="dailymed/index.cfm" title="Home">Home</a></li>						<li>													<a href="#" title="News">												News</a>							<ul class="sub-menu">								<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>								<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>							</ul>						</li>						<li>																				<a href="dailymed/fda-drug-guidance.cfm" title="FDA Guidances &amp; Info">												FDA Guidances &amp; Info</a>													</li>						<li>													<a href="#" title="Structured Product Labeling (SPL) resources for industry professionals.">												NLM SPL Resources</a>														<ul class="sub-menu">								<li><a href="dailymed/spl-resources.cfm">Download Data</a>									<ul>										<li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>										<li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Indexing Files</a></li>										<li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>									</ul>								</li>								<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>								<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>							</ul>						</li>						<li>													<a href="#" title="Application Development Support">												Application Development Support</a>							<ul class="sub-menu">								<li><a href="dailymed/app-support.cfm">Resources</a>									<ul>										<li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>																				<li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>									</ul>								</li>							</ul>						</li>									  						<li>													<a href="dailymed/help.cfm" title="Help">												Help</a></li>   					</ul>					<ul class="tabletview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li><span>News</span>									<ul>										<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>										<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>									</ul>								</li>								<li><span>Safety Reporting and Recalls</span>									<ul>										<li><a href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events</a></li>										<li><a href="/www.fda.gov/Safety/Recalls" target="_blank">FDA Saftey Recalls</a></li>									</ul>								</li>								<li>									<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>								</li>																<li><span>NLM SPL Resources</span>									<ul>										<li><a href="dailymed/spl-resources.cfm">Download Data</a>											<ul>												<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>												<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>												<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>											</ul>										</li>										<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>										<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>									</ul>								</li>   								<li><span>Application Development Support</span>									<ul>										<li><a href="dailymed/app-support.cfm">Resources</a>											<ul>												<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																								<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>											</ul>										</li>									</ul>								</li>   								<li><a href="dailymed/help.cfm" title="Help">Help</a></li>   							</ul>						</li>						<li class="mobileview viewmore" tabindex="0"><a title="View More" href="#">More ways to search</a>							<ul>								<li tabindex="0"><a title="Browse Drug Classes" href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>								<li tabindex="0"><a title="Label Archives" href="dailymed/archives/index.cfm">Label Archives</a></li>																<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool" href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>										<ul class="mobileview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li tabindex="0" class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li tabindex="0"><a href="dailymed/browse-drug-classes.cfm" title="Browse Drug Classes">Browse Drug Classes</a></li>								<li tabindex="0"><a href="dailymed/archives/index.cfm" title="Label Archives">Label Archives</a></li>																<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title="Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>				</nav>				<div class="divider_10 nomargin"></div>			</div>					</div>				<div class="divider"></div>	</div></header><div id="skip-main-content"></div>        <div class="container">             <div class="main-content">                <div class="header long">                    <div class="header-top">                            <h1>Label: <span class="long-title">ABILIFY MAINTENA- aripiprazole   <br></span></h1>                    </div>                                        <ul class="tools">                    	                        <li class="rss"><a href="#modal-label-rss" class="modal-open">Label RSS</a></li>                        <li class="share">Share                            <noscript>: JavaScript needed for Sharing tools</noscript>                            <!-- AddThis Button BEGIN -->                            <div class="addthis_toolbox addthis_default_style addthis_16x16_style">                                                                                                    	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AABILIFY%20MAINTENA%2D%20Aripiprazole%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Dee49f3b1%2D1650%2D47ff%2D9fb1%2Dea53fe0b92b6%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                                <a class="addthis_button_facebook"></a>                                <a class="addthis_button_twitter"></a>                                                                <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="display: block;">                                    <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span><img style="width:17px" src="/dailymed/images/addthis-image.jpg"></img>                                </a>                            </div>                            <script type="text/javascript">var addthis_config = {"data_track_addressbar":false};</script>                            <script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5" ></script>                             <!-- AddThis Button END -->                                                    </li>                    </ul>                  </div>                <div class="four columns sidebar" id="leftmenu">                    <section>                        <article>                                                        <div class="w-photos">                            	                                                                <div class="mod drug-photos">                                <h2><a>View Package Photos</a></h2>                                <ul>                                    <li>                                                                               <ul>                                                                                                                        	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=300 mg vial label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="0">                                                 	<img id="zoom_1" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=300 mg vial label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" src="image.cfm?type=img&name=300 mg vial label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=300 mg Vial Carton.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="1">                                                 	<img id="zoom_2" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=300 mg Vial Carton.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" src="image.cfm?type=img&name=300 mg Vial Carton.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                </ul>                                    </li>                                </ul>								                                    <h4 class="more closed">VIEW MORE</h4>                                        <div class="show-more">                                            <ul>                                                                                                                        <li>                                                <ul>                                                                                    <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=400 mg Vial Label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="2">                                                <img id="zoom_3" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=400 mg Vial Label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" src="image.cfm?type=img&name=400 mg Vial Label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                                                                                                                                           <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=400 mg vial carton.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="3">                                                <img id="zoom_4" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=400 mg vial carton.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" src="image.cfm?type=img&name=400 mg vial carton.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                         </ul>                                             </li>                                                                                                                                                                                                           <li>                                                <ul>                                                                                    <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=Sterile Water Label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="4">                                                <img id="zoom_5" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=Sterile Water Label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" src="image.cfm?type=img&name=Sterile Water Label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                                                                                                                                           <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=300 mg Syringe Label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="5">                                                <img id="zoom_6" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=300 mg Syringe Label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" src="image.cfm?type=img&name=300 mg Syringe Label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                         </ul>                                             </li>                                                                                                                                                                                                           <li>                                                <ul>                                                                                    <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=300 mg Syringe Carton Label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="6">                                                <img id="zoom_7" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=300 mg Syringe Carton Label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" src="image.cfm?type=img&name=300 mg Syringe Carton Label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                                                                                                                                           <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=400 mg Syringe Label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="7">                                                <img id="zoom_8" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=400 mg Syringe Label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" src="image.cfm?type=img&name=400 mg Syringe Label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                         </ul>                                             </li>                                                                                                                                                                                                           <li>                                                <ul>                                                                                    <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=400 mg Syringe Carton Label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="8">                                                <img id="zoom_9" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=400 mg Syringe Carton Label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" src="image.cfm?type=img&name=400 mg Syringe Carton Label.jpg&setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                         </ul>                                             </li>                                                                                                                                                            </ul>                                     </div>                                                                 </div>            								                                                                                            </div>                            <div class="mod-wrap">                                <div class="mod blue-list page-jump">                                    <h2><a href="#drug-information">Drug Label Info</a></h2>                                </div>                                                                <div class="mod blue-list orange">                                                                                                                                                                                                                                                                                                                                                                            <h2><a href="#">Safety</a></h2>                                    <ul>                                                                                    <li>                                                <a class="tip" rel="tooltip" title="A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects." href="#boxedwarning">Boxed Warnings</a>                                            </li>                                                                                                                                                                    <li>                                                <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>                                            </li>                                            <li><a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a></li>                                            <li>                                                <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22aripiprazole%22+%29" target="_blank">Presence in Breast Milk</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">Related Resources</a></h2>                                    <ul>                                                                                                                            <li>                                                <a href="/vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=aripiprazole" target="_blank">Medline Plus</a>                                            </li>                                                                                <li>                                            <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=aripiprazole" target="blank">Clinical Trials</a>                                        </li>                                                                                    <li>                                                <a href="#" id="pubmed-menu">PubMed</a>                                            	    											                                                                                                <ul>                                                    <li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=aripiprazole[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=aripiprazole/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=aripiprazole/TU"  title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=aripiprazole/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=aripiprazole[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a>                                                    </li>                                                </ul>                                            </li>                                            <li>                                                <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=APRD00638&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">More Info For This Drug</a></h2>                                    <ul>                                    	                                        <li><a href="#modal-label-archives" class="modal-open">View Label Archives</a></li>                                        <li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>                                                                                <li><a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a></li>                                    </ul>                                </div>                                                            </div>                        </article>                    </section>                </div>                               <div class="content-wide">                        <article>                            <ul class="drug-information">                            	                                                                <li>                                <strong><a class="tip" rel="tooltip" title="NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." href="#">NDC Code(s):</a></strong> <span id="item-code-s">                                                                                                	                                    59148-018-71,                                                                                                                                        	                                    59148-019-71,                                                                                                                                        	                                    59148-045-80,                                                                                                                                        	                                    59148-072-80                                                                                                                                                                        								</li>                                <li>                                                                                                                                                                <li><strong>Packager: </strong>Otsuka America Pharmaceutical, Inc.</li>                                						    	    																																			    																	    	    	                             		       	                                                                                                                                                           </ul>                                                        <ul class="drug-information">                            	                                <li><strong>Category:</strong>                                 	                                    	<span id="category" class="orangetext">                                                                            	HUMAN PRESCRIPTION DRUG LABEL</span></li>                                                                    <li><strong>DEA Schedule:</strong> <span id="dea-schedule">                                                                        	None                                                                        </span></li>                                                                    <li><strong>Marketing Status:</strong> <span id="marketing-status">New Drug Application</span></li>								                            </ul>							                                    <div id="drug-information" class="toggle">                                                                                    <h2><a id="druglabel"></a>Drug Label Information</h2>                                                 <p class="date">Updated                                                  	                                                    	12/14                                                                                                     </p>                                                   <p class="orangetext">If you are a consumer or patient please visit <a href="dailymed/drugInfo.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&audience=consumer">this version.</a></p>                                                                                                   <ul class="tools">                                                    <li class="download">Download DRUG LABEL INFO: <a class="pdf" href="dailymed/getFile.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&amp;type=pdf&amp;name=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" target="_blank">PDF</a>                                                    	<a class="xml" href="dailymed/getFile.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&amp;type=zip&amp;name=WATER">XML</a>                                                    </li>                                                                                                                                                            <li class="medguide">Medication Guide:                                                         <a href="dailymed/medguide.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" target="_blank">HTML</a>                                                                                                            </li>                                                                                                        <li class="print">                                                        <a href="dailymed/fda/fdaDrugXsl.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&amp;type=display" target="_blank">Print Drug Label Info</a>                                                    </li>                                                                                                    </ul>                                                                                                  <div class="drug-label-sections">                                                   <div class="control-nav show-js">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                                                        <ul>                                                                                        	                                                <li id="boxedwarning"><a href="#">BOXED WARNING</a><a class=" tip" rel="tooltip" href="#" title="A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects.">(What is this?)</a> <div class="Warning toggle-content open">   <a name="BOX"></a>  <a name="section-1"></a>   <p></p>   <h1> <span class="Emphasis">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS</span> </h1>   <p class="First"> <span class="Bold">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY MAINTENA is not approved for the treatment of patients with dementia-related psychosis <span class="Italics">[see </span></span><span class="Bold"><span class="Italics"><a href="#S5.1">WARNINGS AND PRECAUTIONS (5.1)</a></span></span><span class="Bold"><span class="Italics">]</span>.</span> </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">HIGHLIGHTS OF PRESCRIBING INFORMATION</a> <div id="Highlights" class=" Highlights toggle-content closed">    <div class="HighlightsDisclaimer">   These highlights do not include all the information needed to use ABILIFY MAINTENA safely and effectively. See full prescribing information for ABILIFY MAINTENA.   <br />    <br />ABILIFY MAINTENA   <span class="Sup">&reg;</span> (aripiprazole) for extended-release injectable suspension, for intramuscular use   <br />Initial U.S. Approval: 2002  </div>   <div class="Warning">    <div>     <h1 class="Warning">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS</h1>     <h1 class="Warning"> <span class="Italics">See full prescribing information for complete boxed warning.</span> </h1>     <dl>      <dt>      •     </dt>      <dd>       <span class="Bold">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death (<a href="#S5.1">5.1</a>)</span>      </dd>      <dt>      •     </dt>      <dd>       <span class="Bold">ABILIFY MAINTENA is not approved for the treatment of patients with dementia-related psychosis (<a href="#S5.1">5.1</a>)</span>      </dd>     </dl>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>RECENT MAJOR CHANGES</span> </h1>    <div>     <p class="Highlighta"> </p>     <p class="Highlighta">Dosage and Administration, Pre-filled Dual Chamber Syringe (<a href="#S2.5">2.5</a>) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;09/2014 </p>     <p class="Highlighta">Warnings and Precautions, Metabolic Changes (<a href="#S5.5">5.5</a>), Orthostatic Hypotension (<a href="#S5.6">5.6</a>) &nbsp;&nbsp; 12/2014 </p>    </div>   </div>   <div></div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>INDICATIONS AND USAGE</span> </h1>    <div>     <p class="Highlighta">ABILIFY MAINTENA is an atypical antipsychotic indicated for the treatment of schizophrenia (<a href="#S1">1</a>) </p>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE AND ADMINISTRATION</span> </h1>    <div>     <dl>      <dt>      •     </dt>      <dd>      Only to be administered by intramuscular injection in the gluteal muscle by a healthcare professional (      <a href="#S2.1">2.1</a>)     </dd>      <dt>      •     </dt>      <dd>      For patients na&iuml;ve to aripiprazole, establish tolerability with oral aripiprazole prior to initiating ABILIFY MAINTENA (      <a href="#S2.1">2.1</a>)     </dd>      <dt>      •     </dt>      <dd>      Recommended starting and maintenance dose is 400&nbsp;mg administered monthly as a single injection. Dose can be reduced to 300 mg in patients with adverse reactions (      <a href="#S2.1">2.1</a>)     </dd>      <dt>      •     </dt>      <dd>      In conjunction with first dose, take 14 consecutive days of concurrent oral aripiprazole (10&nbsp;mg to 20&nbsp;mg) or current oral antipsychotic (      <a href="#S2.1">2.1</a>)     </dd>      <dt>      •     </dt>      <dd>      Dosage adjustments are required for missed doses (      <a href="#S2.2">2.2</a>)      </dd>     </dl>     <dl>      <dt>      (a)     </dt>      <dd>      Known CYP2D6 poor metabolizers: Recommended starting and maintenance dose is 300 mg administered monthly as a single injection. (      <a href="#S2.3">2.3</a>)     </dd>      <dt>      (b)     </dt>      <dd>      ABILIFY MAINTENA comes in two types of kits. See instructions for reconstitution/injection/disposal procedures for 1) Pre-filled Dual Chamber Syringe (      <a href="#S2.5">2.5</a>), and 2) Vials (      <a href="#S2.6">2.6</a>).     </dd>     </dl>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div>     <div></div>     <div></div>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE FORMS AND STRENGTHS</span> </h1>    <div>     <dl>      <dt>      &nbsp;     </dt>      <dd>       For extended-release injectable suspension: 300 mg and 400 mg strength lyophilized powder for reconstitution in (      <a href="#S3">3</a>):     </dd>      <dt>      &nbsp;     </dt>      <dd>      • single-dose pre-filled dual chamber syringe     </dd>      <dt>      &nbsp;     </dt>      <dd>      • single-dose vial     </dd>     </dl>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>CONTRAINDICATIONS</span> </h1>    <div>     <p class="Highlighta">Known hypersensitivity to aripiprazole (<a href="#S4">4</a>) </p>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>WARNINGS AND PRECAUTIONS</span> </h1>    <div>     <dl>      <dt>      1.     </dt>      <dd>       <span class="Italics">Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis: </span>Increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack, including fatalities) (      <a href="#S5.2">5.2</a>)     </dd>     </dl>     <dl>      <dt>      •     </dt>      <dd>       <span class="Italics">Neuroleptic Malignant Syndrome: </span>Manage with immediate discontinuation and close monitoring (      <a href="#S5.3">5.3</a>)     </dd>      <dt>      •     </dt>      <dd>       <span class="Italics">Tardive Dyskinesia: </span>Discontinue if clinically appropriate (      <a href="#S5.4">5.4</a>)     </dd>      <dt>      •     </dt>      <dd>       <span class="Italics">Metabolic Changes:</span> Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain (      <a href="#S5.5">5.5</a>)      <dl>        <dt>        -       </dt>        <dd>         <span class="Italics">Hyperglycemia and Diabetes Mellitus: </span>Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with and at risk for diabetes (        <a href="#S5.5">5.5</a>)       </dd>        <dt>        -       </dt>        <dd>         <span class="Italics">Dyslipidemia:</span> Undesirable alterations have been observed in patients treated with atypical antipsychotics (        <a href="#S5.5">5.5</a>)       </dd>        <dt>        -       </dt>        <dd>         <span class="Italics">Weight Gain:</span> Gain in body weight has been observed; clinical monitoring of weight is recommended       </dd>       </dl>      </dd>      <dt>      &nbsp;     </dt>      <dd>      (      <a href="#S5.5">5.5</a>)     </dd>     </dl>     <dl>      <dt>      •     </dt>      <dd>       <span class="Italics">Orthostatic Hypotension: </span>Use with caution in patients with known cardiovascular or cerebrovascular disease (      <a href="#S5.6">5.6</a>)     </dd>      <dt>      •     </dt>      <dd>       <span class="Italics">Leukopenia, Neutropenia, and Agranulocytosis: </span>Perform complete blood counts in patients with a history of a clinically significant low white blood cell count (WBC)/absolute neutrophil count (ANC). Consider discontinuation if clinically significant decline in WBC/ANC in the absence of other causative factors (      <a href="#S5.7">5.7</a>)     </dd>      <dt>      •     </dt>      <dd>       <span class="Italics">Seizures: </span>Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold (      <a href="#S5.8">5.8</a>)     </dd>      <dt>      •     </dt>      <dd>       <span class="Italics">Potential for Cognitive and Motor Impairment:</span> Use caution when operating machinery (      <a href="#S5.9">5.9</a>)     </dd>     </dl>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div>     <div></div>     <div></div>     <div></div>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>ADVERSE REACTIONS</span> </h1>    <div>     <p class="Highlighta">Most commonly observed adverse reactions with ABILIFY MAINTENA (incidence ≥5% and at least twice that for placebo) were increased weight, akathisia, injection site pain, and sedation (<a href="#S6.1">6.1</a>) </p>     <p class="Highlighta"> <span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (<span class="Italics">www.fda.gov/medwatch</span>).</span> </p>    </div>    <div>     <div></div>     <div>      <div></div>      <div></div>      <div></div>      <div></div>      <div></div>      <div></div>      <div></div>      <div></div>      <div></div>      <div></div>     </div>    </div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DRUG INTERACTIONS</span> </h1>    <div>     <p class="Highlighta">Dosage adjustments for patients taking CYP2D6 inhibitors, CYP3A4 inhibitors, or CYP3A4 inducers for greater than 14 days (<a href="#S2.3">2.3</a>): </p>     <table width="75%">      <colgroup>      <col width="64%" />       <col width="23%" />      </colgroup>     <thead>       <tr class="First Last">        <th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Factors</span></th>       <th class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">Adjusted Dose</span></th>       </tr>      </thead>      <tfoot>       <tr>        <td align="left" colspan="2">         <dl class="Footnote">          <dt>           <a href="#footnote-reference-2" name="footnote-2">*</a>          </dt>          <dd>          200 mg and 160 mg dose adjustments are obtained only by using the 300 mg or 400 mg strength vials.         </dd>         </dl> </td>       </tr>      </tfoot>      <tbody>       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" colspan="2"> <p class="Highlighta"> <span class="Bold">CYP2D6 Poor Metabolizers </span> </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule"> <p class="Highlighta">CYP2D6 Poor Metabolizers taking concomitant CYP3A4 inhibitors </p> </td>       <td class="Botrule Rrule"> <p class="Highlighta">200&nbsp;mg<a class="Sup" href="#footnote-2" name="footnote-reference-2">*</a> </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" colspan="2"> <p class="Highlighta"> <span class="Bold">Patients Taking 400&nbsp;mg of ABILIFY MAINTENA</span> </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule"> <p class="Highlighta">Strong CYP2D6 <span class="Bold"><span class="Underline">or</span></span> CYP3A4 inhibitors </p> </td>       <td class="Botrule Rrule"> <p class="Highlighta">300&nbsp;mg </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule"> <p class="Highlighta">CYP2D6 <span class="Bold"><span class="Underline">and</span></span> CYP3A4 inhibitors </p> </td>       <td class="Botrule Rrule"> <p class="Highlighta">200&nbsp;mg<a class="Sup" href="#footnote-2">*</a> </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule"> <p class="Highlighta">CYP3A4 inducers </p> </td>       <td class="Botrule Rrule"> <p class="Highlighta">Avoid use </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" colspan="2"> <p class="Highlighta"> <span class="Bold">Patients Taking 300&nbsp;mg of ABILIFY MAINTENA</span> </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule"> <p class="Highlighta">Strong CYP2D6 <span class="Bold"><span class="Underline">or</span></span> CYP3A4 inhibitors </p> </td>       <td class="Botrule Rrule"> <p class="Highlighta">200&nbsp;mg<a class="Sup" href="#footnote-2">*</a> </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule"> <p class="Highlighta">CYP2D6 <span class="Bold"><span class="Underline">and</span></span> CYP3A4 inhibitors </p> </td>       <td class="Botrule Rrule"> <p class="Highlighta">160&nbsp;mg<a class="Sup" href="#footnote-2">*</a> </p> </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule"> <p class="Highlighta">CYP3A4 inducers </p> </td>       <td class="Botrule Rrule"> <p class="Highlighta">Avoid use </p> </td>       </tr>      </tbody>     </table>    </div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>USE IN SPECIFIC POPULATIONS</span> </h1>    <div>     <dl>      <dt>      •     </dt>      <dd>       <span class="Italics">Pregnancy:</span> May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure (      <a href="#S8.1">8.1</a>)      </dd>      <dt>      •     </dt>      <dd>       <span class="Italics">Nursing Mothers:</span> Discontinue drug or nursing, taking into consideration importance of drug to the mother (      <a href="#S8.3">8.3</a>)     </dd>     </dl>    </div>    <div>     <div>      <div>       <div>        <div></div>       </div>       <div></div>      </div>     </div>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div>    <div></div>    <div></div>   </div>   <div></div>   <div>    <div></div>    <div>     <div></div>    </div>    <div>     <div>      <div></div>     </div>     <div></div>    </div>   </div>   <div>    <div>     <div></div>     <div></div>     <div></div>    </div>    <div>     <div></div>     <div></div>    </div>   </div>   <div></div>   <div>    <div></div>    <div></div>   </div>   <div></div>   <div></div>   <div></div>   <div></div>   <div></div>   <div></div>   <div></div>   <div></div>   <div></div>   <div></div>   <div></div>   <p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>   <p class="HighlightsRevision">Revised: 12/2014</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">FULL PRESCRIBING INFORMATION: CONTENTS*</a> <div id="Index" class=" Index toggle-content closed">    <h1> <a href="#section-1" class="toc"><span class="Emphasis">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS</span></a> </h1>   <h1> <a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a> </h1>   <h1> <a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a> </h1>   <h2> <a href="#section-2.1" class="toc">2.1 Dosage Overview for the Treatment of Schizophrenia</a> </h2>   <h2> <a href="#section-2.2" class="toc">2.2 Dosage Adjustments for Missed Doses</a> </h2>   <h2> <a href="#section-2.3" class="toc">2.3 Dosage Adjustments for Cytochrome P450 Considerations</a> </h2>   <h2> <a href="#section-2.4" class="toc">2.4 Different Aripiprazole Formulations and Kits</a> </h2>   <h2> <a href="#section-2.5" class="toc">2.5 Pre-filled Dual Chamber Syringe: Preparation and Administration Instructions</a> </h2>   <h2> <a href="#section-2.6" class="toc">2.6 Vial: Preparation and Administration Instructions</a> </h2>   <h1> <a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a> </h1>   <h1> <a href="#section-4" class="toc">4 CONTRAINDICATIONS</a> </h1>   <h1> <a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a> </h1>   <h2> <a href="#section-5.1" class="toc">5.1 Increased Mortality in Elderly Patients with Dementia- Related Psychosis</a> </h2>   <h2> <a href="#section-5.2" class="toc">5.2 Cerebrovascular Adverse Reactions, Including Stroke in Elderly Patients with Dementia-Related Psychosis</a> </h2>   <h2> <a href="#section-5.3" class="toc">5.3 Neuroleptic Malignant Syndrome</a> </h2>   <h2> <a href="#section-5.4" class="toc">5.4 Tardive Dyskinesia</a> </h2>   <h2> <a href="#section-5.5" class="toc">5.5 Metabolic Changes</a> </h2>   <h2> <a href="#section-5.6" class="toc">5.6 Orthostatic Hypotension</a> </h2>   <h2> <a href="#section-5.7" class="toc">5.7 Leukopenia, Neutropenia, and Agranulocytosis</a> </h2>   <h2> <a href="#section-5.8" class="toc">5.8 Seizures</a> </h2>   <h2> <a href="#section-5.9" class="toc">5.9 Potential for Cognitive and Motor Impairment</a> </h2>   <h2> <a href="#section-5.10" class="toc">5.10 Body Temperature Regulation</a> </h2>   <h2> <a href="#section-5.11" class="toc">5.11 Dysphagia</a> </h2>   <h1> <a href="#section-6" class="toc">6 ADVERSE REACTIONS</a> </h1>   <h2> <a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a> </h2>   <h2> <a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a> </h2>   <h1> <a href="#section-7" class="toc">7 DRUG INTERACTIONS</a> </h1>   <h2> <a href="#section-7.1" class="toc">7.1 Drugs Having Clinically Important Interactions with ABILIFY MAINTENA</a> </h2>   <h2> <a href="#section-7.2" class="toc">7.2 Drugs Having No Clinically Important Interactions with ABILIFY MAINTENA</a> </h2>   <h1> <a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a> </h1>   <h2> <a href="#section-8.1" class="toc">8.1 Pregnancy</a> </h2>   <h2> <a href="#section-8.2" class="toc">8.3 Nursing Mothers</a> </h2>   <h2> <a href="#section-8.3" class="toc">8.4 Pediatric Use</a> </h2>   <h2> <a href="#section-8.4" class="toc">8.5 Geriatric Use</a> </h2>   <h2> <a href="#section-8.5" class="toc">8.6 CYP2D6 Poor Metabolizers</a> </h2>   <h2> <a href="#section-8.6" class="toc">8.7 Hepatic and Renal Impairment </a> </h2>   <h2> <a href="#section-8.7" class="toc">8.8 Other Specific Populations </a> </h2>   <h1> <a href="#section-9" class="toc">10 OVERDOSAGE</a> </h1>   <h2> <a href="#section-9.1" class="toc">10.1 Human Experience</a> </h2>   <h2> <a href="#section-9.2" class="toc">10.2 Management of Overdosage</a> </h2>   <h1> <a href="#section-10" class="toc">11 DESCRIPTION</a> </h1>   <h1> <a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a> </h1>   <h2> <a href="#section-11.1" class="toc">12.1 Mechanism of Action</a> </h2>   <h2> <a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a> </h2>   <h2> <a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a> </h2>   <h1> <a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a> </h1>   <h2> <a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a> </h2>   <h2> <a href="#section-12.2" class="toc">13.2 Animal Toxicity and/or Pharmacology</a> </h2>   <h1> <a href="#section-13" class="toc">14 CLINICAL STUDIES</a> </h1>   <h1> <a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a> </h1>   <h2> <a href="#section-14.1" class="toc">16.1 How Supplied</a> </h2>   <h2> <a href="#section-14.2" class="toc">16.2 Storage</a> </h2>   <h1> <a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a> </h1>   <dl class="Footnote">    <dt>     <a name="footnote-content" href="#footnote-reference-content">*</a>    </dt>    <dd>    Sections or subsections omitted from the full prescribing information are not listed.   </dd>   </dl>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">1 INDICATIONS AND USAGE</a> <div class="Section toggle-content closed" data-sectioncode="34067-9">   <a name="S1"></a>  <a name="section-1"></a>   <p></p>    <p class="First">ABILIFY MAINTENA (aripiprazole) is indicated for the treatment of schizophrenia <span class="Italics">[see </span><span class="Italics"><a href="#_14_CLINICAL_STUDIES">CLINICAL STUDIES (14)</a></span><span class="Italics">]</span>.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">2 DOSAGE AND ADMINISTRATION</a> <div class="Section toggle-content closed" data-sectioncode="34068-7">   <a name="S2"></a>  <a name="section-2"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S2.1"></a>   <a name="section-2.1"></a>    <p></p>    <h2>2.1 Dosage Overview for the Treatment of Schizophrenia</h2>    <p class="First">ABILIFY MAINTENA is only to be administered by intramuscular injection by a healthcare professional. The recommended starting and maintenance dose of ABILIFY MAINTENA is 400&nbsp;mg monthly (no sooner than 26&nbsp;days after the previous injection).</p>    <p>For patients who have never taken aripiprazole, establish tolerability with oral aripiprazole prior to initiating treatment with ABILIFY MAINTENA. Due to the half-life of oral aripiprazole, it may take up to 2 weeks to fully assess tolerability.</p>    <p>After the first ABILIFY MAINTENA injection, administer oral aripiprazole (10 mg to 20 mg) for 14 consecutive days to achieve therapeutic aripiprazole concentrations during initiation of therapy. For patients already stable on another oral antipsychotic (and known to tolerate aripiprazole), after the first ABILIFY MAINTENA injection, continue treatment with the antipsychotic for 14 consecutive days to maintain therapeutic antipsychotic concentrations during initiation of therapy.</p>    <p>If there are adverse reactions with the 400&nbsp;mg dosage, consider reducing the dosage to 300&nbsp;mg once monthly.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.2"></a>   <a name="section-2.2"></a>    <p></p>    <h2>2.2 Dosage Adjustments for Missed Doses</h2>    <p class="First">If the second or third doses are missed:</p>    <dl>     <dt>     •    </dt>     <dd>      <span class="Bold">If more than 4&nbsp;weeks and less than 5&nbsp;weeks have elapsed since the last injection, </span>administer the injection as soon as possible     <span class="Bold">.</span>     </dd>     <dt>     •    </dt>     <dd>      <span class="Bold">If more than 5&nbsp;weeks have elapsed since the last injection, </span>restart concomitant oral aripiprazole for 14&nbsp;days with the next administered injection.    </dd>    </dl>    <p>If the fourth or subsequent doses are missed:</p>    <dl>     <dt>     •    </dt>     <dd>      <span class="Bold">If more than 4&nbsp;weeks and less than 6&nbsp;weeks have elapsed since the last injection,</span> administer the injection as soon as possible.    </dd>     <dt>     •    </dt>     <dd>      <span class="Bold">If more than 6&nbsp;weeks have elapsed since the last injection,</span> restart concomitant oral aripiprazole for 14&nbsp;days with the next administered injection.    </dd>    </dl>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.3"></a>   <a name="section-2.3"></a>    <p></p>    <h2>2.3 Dosage Adjustments for Cytochrome P450 Considerations</h2>    <p class="First">Dosage adjustments are recommended in patients who are CYP2D6 poor metabolizers and in patients taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors for greater than 14&nbsp;days (see <a href="#_Ref400532082">Table 1</a>). Dosage adjustments for 200 mg and 160 mg are obtained only by using the 300 mg or 400 mg strength vials for intramuscular gluteal injection.</p>    <p>If the CYP3A4 inhibitor or CYP2D6 inhibitor is withdrawn, the ABILIFY MAINTENA dosage may need to be increased <span class="Italics">[see </span><span class="Italics"><a href="#S2.1">DOSAGE AND ADMINISTRATION (2.1)</a></span><span class="Italics">]</span>.</p>    <p>Avoid the concomitant use of CYP3A4 inducers with ABILIFY MAINTENA for greater than 14&nbsp;days because the blood levels of aripiprazole are decreased and may be below the effective levels.</p>    <p>Dosage adjustments are not recommended for patients with concomitant use of CYP3A4 inhibitors, CYP2D6 inhibitors or CYP3A4 inducers for less than 14&nbsp;days.</p>    <a name="_Ref400532082"></a>    <div class="scrollingtable">    <table width="100%">      <caption>       <span>Table 1: Dose Adjustments of ABILIFY MAINTENA in Patients who are Known CYP2D6 Poor Metabolizers and Patients Taking Concomitant CYP2D6 Inhibitors, 3A4 Inhibitors, and/or CYP3A4 Inducers for Greater than 14 days</span>      </caption>      <colgroup>      <col width="70%" />       <col width="30%" />      </colgroup>     <thead>       <tr class="First Last">        <th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Factors</span></th>       <th class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Adjusted Dose</span></th>       </tr>      </thead>      <tfoot>       <tr>        <td align="left" colspan="2">         <dl class="Footnote">          <dt>           <a href="#footnote-reference-1" name="footnote-1">*</a>          </dt>          <dd>          200 mg and 160 mg dosage adjustments are obtained only by using the 300 mg or 400 mg strength vials.         </dd>         </dl> </td>       </tr>      </tfoot>      <tbody>       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" colspan="2"> <p class="First"> <span class="Bold">CYP2D6 Poor Metabolizers</span> </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule"> <p class="First">Known CYP2D6 Poor Metabolizers</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">300&nbsp;mg</p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule"> <p class="First">Known CYP2D6 Poor Metabolizers taking concomitant CYP3A4 inhibitors</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">200&nbsp;mg<a class="Sup" href="#footnote-1" name="footnote-reference-1">*</a> </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" colspan="2"> <p class="First"> <span class="Bold">Patients Taking 400&nbsp;mg of ABILIFY MAINTENA</span> </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule"> <p class="First">Strong CYP2D6 <span class="Bold"><span class="Underline">or</span></span> CYP3A4 inhibitors</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">300&nbsp;mg</p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule"> <p class="First">CYP2D6 <span class="Bold"><span class="Underline">and</span></span> CYP3A4 inhibitors</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">200&nbsp;mg<a class="Sup" href="#footnote-1">*</a> </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule"> <p class="First">CYP3A4 inducers</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">Avoid use</p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" colspan="2"> <p class="First"> <span class="Bold">Patients Taking 300&nbsp;mg of ABILIFY MAINTENA</span> </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule"> <p class="First">Strong CYP2D6 <span class="Bold"><span class="Underline">or</span></span> CYP3A4 inhibitors</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">200&nbsp;mg<a class="Sup" href="#footnote-1">*</a> </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule"> <p class="First">CYP2D6 <span class="Bold"><span class="Underline">and</span></span> CYP3A4 inhibitors</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">160&nbsp;mg<a class="Sup" href="#footnote-1">*</a> </p> </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule"> <p class="First">CYP3A4 inducers</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">Avoid use</p> </td>       </tr>      </tbody>     </table>   </div>    <p>ABILIFY MAINTENA comes in two types of kits. See instructions for reconstitution/injection/disposal procedures for 1) Pre-filled Dual Chamber Syringe (<a href="#S2.5">2.5</a>), and 2) Vials (<a href="#S2.6">2.6</a>).</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.4"></a>   <a name="section-2.4"></a>    <p></p>    <h2>2.4 Different Aripiprazole Formulations and Kits</h2>    <p class="First">There are two aripiprazole formulations for intramuscular use with different dosages, dosing frequencies, and indications. ABILIFY MAINTENA is a long-acting aripiprazole formulation with 4 week dosing intervals indicated for the treatment of schizophrenia. In contrast, aripiprazole injection (9.75 mg per vial) is a short-acting formulation indicated for agitation in patients with schizophrenia or mania. Do not substitute these products. Refer to the prescribing information for aripiprazole injection for more information about aripiprazole injection.</p>    <p>ABILIFY MAINTENA comes in two types of kits. See instructions for reconstitution/injection/disposal procedures for 1) Pre-filled Dual Chamber Syringe available in 300 mg or 400 mg strength syringes <span class="Italics">[see </span><span class="Italics"><a href="#S2.5">DOSAGE AND ADMINISTRATION (2.5)</a></span><span class="Italics">]</span>, and 2) Single-use vials available in 300 mg or 400 mg strength vials <span class="Italics">[see </span><span class="Italics"><a href="#S2.6">DOSAGE AND ADMINISTRATION (2.6)</a></span><span class="Italics">]</span>.</p>    <p>The 200 mg and 160 mg dosage adjustments are obtained only by using the 300 mg or 400 mg strength vials.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.5"></a>   <a name="section-2.5"></a>    <p></p>    <h2>2.5 Pre-filled Dual Chamber Syringe: Preparation and Administration Instructions</h2>    <p class="First"> <span class="Bold">Preparation Prior to Reconstitution </span> </p>    <p style="border-left:1px solid;"> <span class="XmChange"><span class="Bold">For deep intramuscular gluteal injection by healthcare professionals only. Do not administer by any other route. Inject full syringe contents immediately following reconstitution. Administer once monthly.</span></span> </p>    <p style="border-left:1px solid;"> <span class="XmChange">Lay out and confirm that components listed below are provided in the kit:</span> </p>    <dl>     <dt>     (a)    </dt>     <dd>      <span class="XmChange">One ABILIFY MAINTENA (aripiprazole) pre-filled dual chamber syringe (400 mg or 300 mg as appropriate) for extended release injectable suspension containing lyophilized powder and Sterile Water for Injection</span>     </dd>     <dt>     (b)    </dt>     <dd>      <span class="XmChange">One 21 gauge, 1.5 inch (38 mm) hypodermic safety needle with needle protection device for non-obese patients</span>     </dd>     <dt>     (c)    </dt>     <dd>      <span class="XmChange">One 21 gauge, 2 inch (50 mm) hypodermic safety needle with needle protection device for obese patients</span>     </dd>    </dl>    <p> <span class="Bold">Reconstitution of Lyophilized Powder in Pre-filled Dual Chamber Syringe</span> </p>    <p style="border-left:1px solid;"> <span class="XmChange"><span class="Bold"><span class="Italics">Reconstitute at room temperature. </span></span></span> </p>    <dl>     <dt>     a)    </dt>     <dd>      <span class="XmChange">Push plunger rod slightly to engage threads. And then, rotate plunger rod until the rod stops rotating to release diluent. After plunger rod is at complete stop, middle stopper will be at the indicator line (See</span>&nbsp;     <a href="#id1847675492">Figure 1</a>     <span class="XmChange">).</span>     </dd>    </dl>    <div class="Figure">     <a name="id1847675492"></a>    <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%201%2Ejpg" alt="Figure 1" />    <p class="MultiMediaCaption">Figure 1</p>    </div>    <dl>     <dt>     b)    </dt>     <dd>      <span class="XmChange">Vertically shake the syringe vigorously for 20 seconds until drug is uniformly milky-white (See <a href="#id2112082718">Figure 2</a>).</span>     </dd>    </dl>    <div class="Figure">     <a name="id2112082718"></a>    <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%202%2Ejpg" alt="Figure 2" />    <p class="MultiMediaCaption">Figure 2</p>    </div>    <dl>     <dt>     c)    </dt>     <dd>      <span class="XmChange">Visually inspect the syringe for particulate matter and discoloration prior to administration. The reconstituted ABILIFY MAINTENA suspension should appear to be a uniform, homogeneous suspension that is opaque and milky-white in color.</span>     </dd>    </dl>    <p style="border-left:1px solid;"> <span class="XmChange"><span class="Bold">Injection Procedure</span></span> </p>    <p style="border-left:1px solid;"> <span class="XmChange"><span class="Bold"><span class="Italics">Use appropriate aseptic techniques throughout injection procedure. Do not administer intravenously or subcutaneously. </span></span></span> </p>    <dl>     <dt>     a)    </dt>     <dd>      <span class="XmChange">Twist and pull off Over-cap and Tip-cap (See <a href="#id-1849551681">Figure 3</a>).</span>     </dd>    </dl>    <div class="Figure">     <a name="id-1849551681"></a>    <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%203%2Ejpg" alt="Figure 3" />    <p class="MultiMediaCaption">Figure 3</p>    </div>    <dl>     <dt>     b)    </dt>     <dd>      <span class="XmChange">Select appropriate needle (See <a href="#id-667324067">Figure 4</a>).</span>     </dd>    </dl>    <div class="Figure">     <a name="id-667324067"></a>    <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%204%2Ejpg" alt="Figure 4" />    <p class="MultiMediaCaption">Figure 4</p>    </div>    <dl>     <dt>     •    </dt>     <dd>      <span class="XmChange">One 21 gauge, 1.5 inch (38 mm) hypodermic safety needle with needle protection device for non-obese patients </span>     </dd>     <dt>     •    </dt>     <dd>      <span class="XmChange">One 21 gauge, 2 inch (50 mm) hypodermic safety needle with needle protection device for obese patients </span>     </dd>    </dl>    <dl>     <dt>     c)    </dt>     <dd>      <span class="XmChange">While holding the needle cap, ensure the needle is firmly seated on the safety device with a push. Twist clockwise until SNUGLY fitted (See <a href="#id406665631">Figure 5</a>).</span>     </dd>    </dl>    <div class="Figure">     <a name="id406665631"></a>    <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%205%2Ejpg" alt="Figure 5" />    <p class="MultiMediaCaption">Figure 5</p>    </div>    <dl>     <dt>     d)    </dt>     <dd>      <span class="XmChange">Then <span class="Bold">PULL</span> needle-cap straight up (see ).</span>     </dd>    </dl>    <div class="Figure">     <a name="id-2003122383"></a>    <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%206%2Ejpg" alt="Figure 6" />    <p class="MultiMediaCaption">Figure 6</p>    </div>    <dl>     <dt>     e)    </dt>     <dd>      <span class="XmChange">Hold syringe <span class="Bold">UPRIGHT and ADVANCE PLUNGER ROD SLOWLY TO EXPEL THE AIR</span>. Expel air until suspension fills needle base. If it’s not possible to advance plunger rod to expel the air, check that plunder rod is rotated to a complete stop (See <a href="#id-63964469">Figure 7</a>).</span>     </dd>    </dl>    <div class="Figure">     <a name="id-63964469"></a>    <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%207%2Ejpg" alt="Figure 7" />    <p class="MultiMediaCaption">Figure 7</p>    </div>    <dl>     <dt>     f)    </dt>     <dd>      <span class="XmChange"><span class="Bold">Inject slowly</span> into the <span class="Bold">gluteal muscle</span>. Do not <span class="Bold">massage</span> the injection site. Do not administer intravenously or subcutaneously.</span>     </dd>    </dl>    <p style="border-left:1px solid;"> <span class="XmChange"><span class="Bold">Disposal Procedure</span></span> </p>    <dl>     <dt>     a)    </dt>     <dd>      <span class="XmChange">Engage the needle safety device and safely discard all kit components (See <a href="#id1731572554">Figure 8</a>). <span class="Bold">ABILIFY MAINTENA pre-filled dual chamber syringe is for single-use only. </span></span>     </dd>    </dl>    <span class="XmChange">     <div class="Figure">      <a name="id1731572554"></a>     <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%208%2Ejpg" alt="Figure 8" />     <p class="MultiMediaCaption">Figure 8</p>     </div> </span>    <dl>     <dt>     b)    </dt>     <dd>      <span class="XmChange">Rotate sites of injections between the two gluteal muscles.</span>     </dd>    </dl>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.6"></a>   <a name="section-2.6"></a>    <p></p>    <h2>2.6 Vial: Preparation and Administration Instructions</h2>    <p class="First"> <span class="Bold">Preparation Prior to Reconstitution </span> </p>    <p> <span class="Bold">For deep intramuscular gluteal injection by healthcare professionals only. Do not administer by any other route. Inject immediately after reconstitution. Administer once monthly.</span> </p>    <dl>     <dt>     1.    </dt>     <dd>     Lay out and confirm that components listed below are provided in the kit:    </dd>    </dl>    <dl>     <dt>     •    </dt>     <dd>     Vial of ABILIFY MAINTENA (aripiprazole) for extended-release injectable suspension lyophilized powder    </dd>     <dt>     •    </dt>     <dd>     5 mL vial of Sterile Water for Injection, USP    </dd>     <dt>     •    </dt>     <dd>     One 3 mL luer lock syringe with pre-attached 21 gauge, 1.5 inch (38 mm) hypodermic safety needle with needle protection device    </dd>     <dt>     •    </dt>     <dd>     One 3 mL luer lock disposable syringe with luer lock tip    </dd>     <dt>     •    </dt>     <dd>     One vial adapter    </dd>     <dt>     •    </dt>     <dd>     One 21 gauge, 1.5 inch (38 mm) hypodermic safety needle with needle protection device for non-obese patients    </dd>     <dt>     •    </dt>     <dd>     One 21 gauge, 2 inch (50 mm) hypodermic safety needle with needle protection device for obese patients     <br />     </dd>    </dl>    <dl>     <dt>     2.    </dt>     <dd>     ABILIFY MAINTENA should be suspended using the Sterile Water for Injection as supplied in the kit.    </dd>     <dt>     3.    </dt>     <dd>     The Sterile Water for Injection and ABILIFY MAINTENA vials are for single-use only.    </dd>     <dt>     4.    </dt>     <dd>     Use appropriate aseptic techniques throughout reconstitution and reconstitute at room temperature.    </dd>     <dt>     5.    </dt>     <dd>     Select the amount of Sterile Water for Injection needed for reconstitution (see      <a href="#_Ref400531953">Table 2</a>).    </dd>    </dl>    <a name="_Ref400531953"></a>    <div class="scrollingtable">    <table width="100%">      <caption>       <span>Table 2: Amount of Sterile Water for Injection Needed for Reconstitution</span>      </caption>      <colgroup>      <col width="23%" />       <col width="23%" />       <col width="23%" />       <col width="23%" />      </colgroup>     <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"> <p class="First"> <span class="Bold">400 mg Vial</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"> <p class="First"> <span class="Bold">300 mg Vial</span> </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center"> <p class="First">Dose</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">Sterile Water for Injection</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">Dose</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">Sterile Water for Injection</p> </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">400 mg</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">1.9 mL</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">300 mg</p> </td>       <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">1.5 mL</p> </td>       </tr>      </tbody>     </table>   </div>    <p> <span class="Bold">Important: There is more Sterile Water for Injection in the vial than is needed to reconstitute ABILIFY MAINTENA (aripiprazole) for extended-release injectable suspension. The vial will have excess Sterile Water for Injection; discard any unused portion.</span> </p>    <p> <span class="Bold">Reconstitution of Lyophilized Powder in Vial </span> </p>    <dl>     <dt>     a)    </dt>     <dd>     Remove the cap of the vial of Sterile Water for Injection and remove the cap of the vial containing ABILIFY MAINTENA lyophilized powder and wipe the tops with a sterile alcohol swab.    </dd>     <dt>     b)    </dt>     <dd>     Using the syringe with pre-attached hypodermic safety needle, withdraw the pre-determined Sterile Water for Injection volume from the vial of Sterile Water for Injection into the syringe (see      <a href="#id-590167771">Figure 9</a>). Residual Sterile Water for Injection will remain in the vial following withdrawal; discard any unused portion.    </dd>    </dl>    <div class="Figure">     <a name="id-590167771"></a>    <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%209%2Ejpg" alt="Figure 9" />    <p class="MultiMediaCaption">Figure 9</p>    </div>    <dl>     <dt>     c)    </dt>     <dd>     Slowly inject the Sterile Water for Injection into the vial containing the ABILIFY MAINTENA lyophilized powder (see      <a href="#id-1874688196">Figure 10</a>).    </dd>    </dl>    <div class="Figure">     <a name="id-1874688196"></a>    <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%2010%2Ejpg" alt="Figure 10" />    <p class="MultiMediaCaption">Figure 10</p>    </div>    <dl>     <dt>     d)    </dt>     <dd>     Withdraw air to equalize the pressure in the vial by pulling back slightly on the plunger. Subsequently, remove the needle from the vial. Engage the needle safety device by using the one-handed technique (see      <a href="#id-811024495">Figure 11</a>). Gently press the sheath against a flat surface until the needle is firmly engaged in the needle protection sheath. Visually confirm that the needle is fully engaged into the needle protection sheath, and discard.    </dd>    </dl>    <div class="Figure">     <a name="id-811024495"></a>    <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%2011%2Ejpg" alt="Figure 11" />    <p class="MultiMediaCaption">Figure 11</p>    </div>    <dl>     <dt>     e)    </dt>     <dd>     Shake the vial vigorously for 30 seconds until the reconstituted suspension appears uniform (see      <a href="#id257489039">Figure 12</a>).    </dd>    </dl>    <div class="Figure">     <a name="id257489039"></a>    <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%2012%2Ejpg" alt="Figure 12" />    <p class="MultiMediaCaption">Figure 12</p>    </div>    <dl>     <dt>     f)    </dt>     <dd>     Visually inspect the reconstituted suspension for particulate matter and discoloration prior to administration. The reconstituted ABILIFY MAINTENA is a uniform, homogeneous suspension that is opaque and milky-white in color.    </dd>     <dt>     g)    </dt>     <dd>     If the injection is not performed immediately after reconstitution keep the vial at room temperature and shake the vial vigorously for at least 60 seconds to re-suspend prior to injection.    </dd>     <dt>     h)    </dt>     <dd>     Do not store the reconstituted suspension in a syringe.    </dd>    </dl>    <p> <span class="Bold">Preparation Prior to Injection</span> </p>    <dl>     <dt>     1.    </dt>     <dd>     Use appropriate aseptic techniques throughout injection of the reconstituted ABILIFY MAINTENA suspension.    </dd>     <dt>     2.    </dt>     <dd>     Remove the cover from the vial adapter package (see      <a href="#fig5">Figure 13</a>). Do not remove the vial adapter from the package.    </dd>    </dl>    <div class="Figure">     <a name="fig5"></a>    <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%2013%2Ejpg" alt="Figure 13" />    <p class="MultiMediaCaption">Figure 13</p>    </div>    <dl>     <dt>     3.    </dt>     <dd>     Using the vial adapter package to handle the vial adapter, attach the prepackaged luer lock syringe to the vial adapter (see      <a href="#fig6">Figure 14</a>).    </dd>    </dl>    <div class="Figure">     <a name="fig6"></a>    <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%2014%2Ejpg" alt="Figure 14" />    <p class="MultiMediaCaption">Figure 14</p>    </div>    <dl>     <dt>     4.    </dt>     <dd>     Use the luer lock syringe to remove the vial adapter from the package and discard the vial adapter package (see      <a href="#fig7">Figure 15</a>).      <span class="Underline">Do not touch the spike tip of the adapter at any time</span>     <span class="Bold">.</span>     </dd>    </dl>    <div class="Figure">     <a name="fig7"></a>    <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%2015%2Ejpg" alt="Figure 15" />    <p class="MultiMediaCaption">Figure 15</p>    </div>    <dl>     <dt>     5.    </dt>     <dd>     Determine the recommended volume for injection (     <a href="#_Ref400532442">Table 3</a>).    </dd>    </dl>    <a name="_Ref400532442"></a>    <div class="scrollingtable">    <table width="100%">      <caption>       <span>Table 3: ABILIFY MAINTENA Reconstituted Suspension Volume to Inject</span>      </caption>      <colgroup>      <col width="20%" />       <col width="30%" />       <col width="20%" />       <col width="30%" />      </colgroup>     <thead>       <tr class="First Last">        <th class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">400&nbsp;mg Vial</span></th>       <th class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">300&nbsp;mg Vial</span></th>       </tr>      </thead>      <tbody>       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="center"> <p class="First">Dose</p> </td>       <td class="Botrule Rrule Toprule" align="center"> <p class="First">Volume to Inject</p> </td>       <td class="Botrule Rrule Toprule" align="center"> <p class="First">Dose</p> </td>       <td class="Botrule Rrule Toprule" align="center"> <p class="First">Volume to Inject</p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center"> <p class="First">400&nbsp;mg</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">2&nbsp;mL</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">---</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">---</p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center"> <p class="First">300&nbsp;mg</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">1.5&nbsp;mL</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">300&nbsp;mg</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">1.5&nbsp;mL</p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center"> <p class="First">200&nbsp;mg</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">1&nbsp;mL</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">200&nbsp;mg</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">1&nbsp;mL</p> </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" align="center"> <p class="First">160&nbsp;mg</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">0.8&nbsp;mL</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">160&nbsp;mg</p> </td>       <td class="Botrule Rrule" align="center"> <p class="First">0.8&nbsp;mL</p> </td>       </tr>      </tbody>     </table>   </div>    <dl>     <dt>     6.    </dt>     <dd>     Wipe the top of the vial of the reconstituted ABILIFY MAINTENA suspension with a sterile alcohol swab.    </dd>     <dt>     7.    </dt>     <dd>     Place and hold the vial of the reconstituted ABILIFY MAINTENA suspension on a hard surface. Attach the adapter-syringe assembly to the vial by holding the outside of the adapter and pushing the adapter's spike firmly through the rubber stopper, until the adapter snaps in place (see      <a href="#fig8">Figure 16</a>).    </dd>    </dl>    <div class="Figure">     <a name="fig8"></a>    <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%2016%2Ejpg" alt="Figure 16" />    <p class="MultiMediaCaption">Figure 16</p>    </div>    <dl>     <dt>     8.    </dt>     <dd>     Slowly withdraw the recommended volume from the vial into the luer lock syringe to allow for injection (see      <a href="#fig9">Figure 17</a>).      <span class="Underline">A small amount of excess product will remain in the vial.</span>     </dd>    </dl>    <div class="Figure">     <a name="fig9"></a>    <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%2017%2Ejpg" alt="Figure 17" />    <p class="MultiMediaCaption">Figure 17</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="S2.7"></a>    <a name="section-2.6.1"></a>     <p></p>     <h3> <span class="Bold">Injection Procedure</span> </h3>     <dl>      <dt>      1.     </dt>      <dd>      Detach the luer lock syringe containing the recommended volume of reconstituted ABILIFY MAINTENA suspension from the vial.     </dd>      <dt>      2.     </dt>      <dd>      Select one of the following hypodermic safety needles and attach the needle to the luer lock syringe containing the suspension for injection. While holding the needle, ensure the needle is firmly seated on the safety device with a push. Twist clockwise until snugly fitted and then pull the needle cap straight away from the needle (see       <a href="#id">Figure 18</a>).     </dd>     </dl>     <dl>      <dt>      •     </dt>      <dd>      21&nbsp;gauge, 1.5&nbsp;inch (38&nbsp;mm) hypodermic safety needle with needle protection device for non-obese patients     </dd>      <dt>      •     </dt>      <dd>      21&nbsp;gauge, 2&nbsp;inch (50&nbsp;mm) hypodermic safety needle with needle protection device for obese patients     </dd>     </dl>     <div class="Figure">      <a name="id1549951480"></a>     <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%2018%2Ejpg" alt="Figure 18" />     <p class="MultiMediaCaption">Figure 18</p>     </div>     <dl>      <dt>      3.     </dt>      <dd>      Slowly inject the recommended volume as a single intramuscular injection into the gluteal muscle. Do not massage the injection site. Do not administer intravenously or subcutaneously      <span class="Italics">.</span>      </dd>     </dl>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="s2.8"></a>    <a name="section-2.6.2"></a>     <p></p>     <h3> <span class="Bold">Disposal Procedure</span> </h3>     <dl>      <dt>      1.     </dt>      <dd>      Engage the needle safety device as described in Section 2.6, Step (d) of Reconstitution of Lyophilized Powder in Vial and safely discard all kit components (see Figure 8). Dispose of the vials, adapter, needles, and syringe appropriately after injection.       <span class="Bold">The Sterile Water for Injection and ABILIFY MAINTENA vials are for single-use only.</span>      </dd>      <dt>      2.     </dt>      <dd>      Rotate sites of injections between the two gluteal muscles.     </dd>     </dl>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">3 DOSAGE FORMS AND STRENGTHS</a> <div class="Section toggle-content closed" data-sectioncode="43678-2">   <a name="S3"></a>  <a name="section-3"></a>   <p></p>    <p class="First"> <span class="Italics">For extended-release injectable suspension: </span>300 mg and 400 mg of lyophilized powder for reconstitution in:</p>   <dl>    <dt>    1.   </dt>    <dd>    single-dose pre-filled dual chamber syringe   </dd>    <dt>    2.   </dt>    <dd>    single-dose vial   </dd>   </dl>   <p>The reconstituted extended-release injectable suspension is a uniform, homogeneous suspension that is opaque and milky-white in color.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">4 CONTRAINDICATIONS</a> <div class="Section toggle-content closed" data-sectioncode="34070-3">   <a name="S4"></a>  <a name="section-4"></a>   <p></p>    <p class="First">ABILIFY MAINTENA is contraindicated in patients with a known hypersensitivity to aripiprazole. Hypersensitivity reactions ranging from pruritus/urticaria to anaphylaxis have been reported in patients receiving aripiprazole <span class="Italics">[see </span><span class="Italics"><a href="#S6.2">ADVERSE REACTIONS (6.1 and 6.2)</a></span><span class="Italics">]</span>.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">5 WARNINGS AND PRECAUTIONS</a> <div class="Section toggle-content closed" data-sectioncode="43685-7">   <a name="S5"></a>  <a name="section-5"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S5.1"></a>   <a name="section-5.1"></a>    <p></p>    <h2>5.1 Increased Mortality in Elderly Patients with Dementia- Related Psychosis</h2>    <p class="First">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10&nbsp;weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.</p>    <p>Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. ABILIFY MAINTENA is not approved for the treatment of patients with dementia-related psychosis.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.2"></a>   <a name="section-5.2"></a>    <p></p>    <h2>5.2 Cerebrovascular Adverse Reactions, Including Stroke in Elderly Patients with Dementia-Related Psychosis</h2>    <p class="First">In placebo-controlled clinical studies (two flexible dose and one fixed dose study) of dementia-related psychosis, there was an increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities, in oral aripiprazole-treated patients (mean age: 84&nbsp;years; range: 78-88&nbsp;years). In the fixed-dose study, there was a statistically significant dose response relationship for cerebrovascular adverse reactions in patients treated with oral aripiprazole. ABILIFY MAINTENA is not approved for the treatment of patients with dementia-related psychosis<span class="Italics">.</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.3"></a>   <a name="section-5.3"></a>    <p></p>    <h2>5.3 Neuroleptic Malignant Syndrome</h2>    <p class="First">A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) may occur with administration of antipsychotic drugs, including ABILIFY MAINTENA. Rare cases of NMS occurred during aripiprazole treatment in the worldwide clinical database.</p>    <p>Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.</p>    <p>The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to exclude cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.</p>    <p>The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.</p>    <p>If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.4"></a>   <a name="section-5.4"></a>    <p></p>    <h2>5.4 Tardive Dyskinesia</h2>    <p class="First">A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.</p>    <p>The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.</p>    <p>There is no known treatment for established tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and, thereby, may possibly mask the underlying process. The effect of symptomatic suppression on the long-term course of the syndrome is unknown.</p>    <p>Given these considerations, ABILIFY MAINTENA should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that 1) is known to respond to antipsychotic drugs and 2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.</p>    <p>If signs and symptoms of tardive dyskinesia appear in a patient treated with ABILIFY MAINTENA drug discontinuation should be considered. However, some patients may require treatment with ABILIFY MAINTENA despite the presence of the syndrome.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.5"></a>   <a name="section-5.5"></a>    <p></p>    <h2>5.5 Metabolic Changes</h2>    <p class="First">Atypical antipsychotic drugs have been associated with metabolic changes that include hyperglycemia/diabetes mellitus, dyslipidemia, and weight gain. While all drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile. </p>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_2c579d56-b11f-4a14-a651-6cfbe64f5a32"></a>    <a name="section-5.5.1"></a>     <p></p>     <p class="First" style="border-left:1px solid;"> <span class="XmChange"><span class="Bold">Hyperglycemia/Diabetes Mellitus</span></span> </p>     <p style="border-left:1px solid;"> <span class="XmChange">Hyperglycemia, in some cases extreme and associated with diabetic ketoacidosis, hyperosmolar coma, or death, has been reported in patients treated with atypical antipsychotics. There have been reports of hyperglycemia in patients treated with aripiprazole [see </span><span class="XmChange"><a href="#S6.1">ADVERSE REACTIONS (6.1)</a></span><span class="XmChange">]. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse reactions is not completely understood. However, epidemiological studies suggest an increased risk of hyperglycemia-related adverse reactions in patients treated with the atypical antipsychotics. Because aripiprazole was not marketed at the time these studies were performed, it is not known if aripiprazole is associated with this increased risk. Precise risk estimates for hyperglycemia-related adverse reactions in patients treated with atypical antipsychotics are not available. Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes), who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.</span> </p>     <p>In a short-term, placebo-controlled randomized trial in adults with schizophrenia, the mean change in fasting glucose was +9.8 mg/dL (N=88) in the ABILIFY MAINTENA- treated patients and +0.7 mg/dL (N=59) in the placebo-treated patients. Table 4 shows the proportion of ABILIFY MAINTENA-treated patients with normal and borderline fasting glucose at baseline and their changes in fasting glucose measurements. </p>     <p style="border-left:1px solid;"> <span class="XmChange"><span class="Bold">Table 4: Proportion of Patients with Potential Clinically Relevant Changes in Fasting Glucose from a 12-Week Placebo-Controlled Monotherapy Trial in Adult Patients with Schizophrenia</span></span> </p>     <div class="scrollingtable">     <table width="96.22%">       <colgroup>       <col width="12%" />        <col width="39%" />        <col width="31%" />        <col width="11%" />        <col width="7%" />       </colgroup>      <thead>        <tr class="First Last">         <th class="Toprule" align="left" valign="top"></th>        <th class="Botrule Toprule" align="left" valign="top"><span class="XmChange"><span class="Bold">Category Change (at least once) from Baseline</span></span></th>        <th class="Botrule Toprule" align="left" valign="bottom"><span class="XmChange"><span class="Bold">Treatment Arm</span></span></th>        <th class="Botrule Toprule" align="left" valign="bottom"><span class="XmChange"><span class="Bold">n/Na</span></span></th>        <th class="Botrule Toprule" align="left" valign="bottom"><span class="XmChange"><span class="Bold">%</span></span></th>        </tr>       </thead>       <tbody>        <tr class="First">         <td class="Botrule" rowspan="4" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange"><span class="Bold">Fasting Glucose<br /> </span></span> </p> </td>        <td class="Botrule Toprule" rowspan="2"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Normal to High<br />(&lt;100&nbsp;mg/dL to ≥126&nbsp;mg/dL)</span> </p> </td>        <td class="Botrule Toprule"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">ABILIFY MAINTENA</span> </p> </td>        <td class="Botrule Toprule"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">7/88</span> </p> </td>        <td class="Botrule Toprule"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">8.0</span> </p> </td>        </tr>        <tr>         <td class="Botrule"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Placebo</span> </p> </td>        <td class="Botrule"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">0/75</span> </p> </td>        <td class="Botrule"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">0.0</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" rowspan="2"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Borderline to High<br />(≥100&nbsp;mg/dL and &lt;126&nbsp;mg/dL to ≥126&nbsp;mg/dL)</span> </p> </td>        <td class="Botrule Toprule"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">ABILIFY MAINTENA</span> </p> </td>        <td class="Botrule Toprule"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">1/33</span> </p> </td>        <td class="Botrule Toprule"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">3.0</span> </p> </td>        </tr>        <tr class="Last">         <td class="Botrule Toprule"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Placebo</span> </p> </td>        <td class="Botrule Toprule"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">3/33</span> </p> </td>        <td class="Botrule Toprule"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">9.1</span> </p> </td>        </tr>       </tbody>      </table>    </div>     <p style="border-left:1px solid;"> <span class="XmChange">a N = the total number of subjects who had a measurement at baseline and at least one post-baseline result.</span> </p>     <p style="border-left:1px solid;"> <span class="XmChange"> n = the number of subjects with a potentially clinically relevant shift.</span> </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_0b02e65b-891b-4914-8b38-56e8b089ddfc"></a>    <a name="section-5.5.2"></a>     <p></p>     <p class="First" style="border-left:1px solid;"> <span class="XmChange"><span class="Bold">Dyslipidemia</span></span> </p>     <p style="border-left:1px solid;"> <span class="XmChange">Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.</span> </p>     <p style="border-left:1px solid;"> <span class="XmChange">Table 5 shows the proportion of adult patients from one short-term, placebo-controlled randomized trial in adults with schizophrenia taking ABILIFY MAINTENA, with changes in total cholesterol, fasting triglycerides, fasting LDL cholesterol and HDL cholesterol.</span> </p>     <p style="border-left:1px solid;"> <span class="XmChange"><span class="Bold">Table 5: Proportion of Patients with Potential Clinically Relevant Changes in Blood Lipid Parameters From a 12-Week Placebo-Controlled Monotherapy Trial in Adults with Schizophrenia</span></span> </p>     <div class="scrollingtable">     <table width="76.86%">       <colgroup>       <col width="33%" />        <col width="29%" />        <col width="16%" />        <col width="10%" />       </colgroup>      <thead>        <tr class="First Last">         <th class="Toprule" align="left" valign="top"></th>        <th class="Botrule Toprule" align="center" valign="top"><span class="XmChange"><span class="Bold">Treatment Arm</span></span></th>        <th class="Botrule Toprule" align="center" valign="top"><span class="XmChange"><span class="Bold">n/Na</span></span></th>        <th class="Botrule Toprule" align="center" valign="top"><span class="XmChange"><span class="Bold">%</span></span></th>        </tr>       </thead>       <tbody>        <tr class="First">         <td class="Botrule" rowspan="2" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange"><span class="Bold">Total Cholesterol</span> <br />Normal to High<br />(&lt;200&nbsp;mg/dL to ≥240&nbsp;mg/dL)</span> </p> </td>        <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">ABILIFY MAINTENA</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">3/83</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">3.6</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Placebo</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">2/73</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">2.7</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" rowspan="2" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Borderline to High</span> </p> <p style="border-left:1px solid;"> <span class="XmChange">(200~&lt;240 mg/dL to ≥240 mg/dL)</span> </p> </td>        <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">ABILIFY MAINTENA</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">6/27</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">22.2</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Placebo</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">2/19</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">10.5</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" rowspan="2" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Any increase </span> </p> <p style="border-left:1px solid;"> <span class="XmChange">(≥40 mg/dL)</span> </p> </td>        <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">ABILIFY MAINTENA</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">15/122</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">12.3</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Placebo</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">6/110</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">5.5</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" rowspan="2" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange"><span class="Bold">Fasting Triglycerides</span> <br />Normal to High<br />(&lt;150&nbsp;mg/dL to ≥200&nbsp;mg/dL)</span> </p> </td>        <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">ABILIFY MAINTENA</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">7/98</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">7.1</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Placebo</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">4/78</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">5.1</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" rowspan="2" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Borderline to High</span> </p> <p style="border-left:1px solid;"> <span class="XmChange">(150~&lt;200 mg/dL to ≥200 mg/dL)</span> </p> </td>        <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">ABILIFY MAINTENA</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">3/11</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">27.3</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Placebo</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">4/15</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">26.7</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" rowspan="2" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Any increase</span> </p> <p style="border-left:1px solid;"> <span class="XmChange">( ≥ 50 mg/dL)</span> </p> </td>        <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">ABILIFY MAINTENA</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">24/122</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">19.7</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Placebo</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">20/110</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">18.2</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" rowspan="2" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange"><span class="Bold">Fasting LDL Cholesterol</span> <br />Normal to High<br />(&lt;100&nbsp;mg/dL to ≥160&nbsp;mg/dL)</span> </p> </td>        <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">ABILIFY MAINTENA</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">1/59</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">1.7</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Placebo</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">1/51</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">2.0</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" rowspan="2" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Borderline to High</span> </p> <p style="border-left:1px solid;"> <span class="XmChange">(100~&lt;160 mg/dL to ≥160 mg/dL)</span> </p> </td>        <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">ABILIFY MAINTENA</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">5/52</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">9.6</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Placebo</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">1/41</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">2.4</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" rowspan="2" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Any increase</span> </p> <p style="border-left:1px solid;"> <span class="XmChange">( ≥ 30 mg/dL)</span> </p> </td>        <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">ABILIFY MAINTENA</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">17/120</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">14.2</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Placebo</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">9/103</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">8.7</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" rowspan="2" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange"><span class="Bold">HDL Cholesterol</span> <br />Normal to Low<br />(≥40&nbsp;mg/dL to &lt;40&nbsp;mg/dL)</span> </p> </td>        <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">ABILIFY MAINTENA</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">14/104</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">13.5</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Placebo</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">11/87</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">12.6</span> </p> </td>        </tr>        <tr>         <td class="Botrule Toprule" rowspan="2" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Any decrease</span> </p> <p style="border-left:1px solid;"> <span class="XmChange">( ≥ 20 mg/dL)</span> </p> </td>        <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">ABILIFY MAINTENA</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">7/122</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">5.7</span> </p> </td>        </tr>        <tr class="Last">         <td class="Botrule Toprule" align="center" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">Placebo</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">12/110</span> </p> </td>        <td class="Botrule Toprule" valign="middle"> <p class="First" style="border-left:1px solid;"> <span class="XmChange">10.9</span> </p> </td>        </tr>       </tbody>      </table>    </div>     <p style="border-left:1px solid;"> <span class="XmChange">a N = the total number of subjects who had a measurement at baseline and at least one post-baseline result. </span> </p>     <p style="border-left:1px solid;"> <span class="XmChange">n = the number of subjects with a potentially clinically relevant shift.</span> </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_9fe84796-7c47-4296-bb8f-8ad52b29c001"></a>    <a name="section-5.5.3"></a>     <p></p>     <p class="First"> <span class="Bold">Weight Gain</span> </p>     <p>Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.</p>     <p style="border-left:1px solid;"> <span class="XmChange">In one short-term, placebo-controlled trial with ABILIFY MAINTENA, the mean change in body weight at Week 12 was +3.5 kg (N=99) in the ABILIFY MAINTENA-treated patients and +0.8 kg (N=66) in the placebo-treated patients. </span> </p>     <p style="border-left:1px solid;"> <span class="XmChange">Table 6 shows the percentage of adult patients with weight gain ≥7% of body weight in a short-term, placebo-controlled trial with ABILIFY MAINTENA. </span> </p>     <p style="border-left:1px solid;"> <span class="XmChange"><span class="Bold">Table 6: Percentage of Patients From a 12-Week Placebo-Controlled Trial in Adult Patients with Schizophrenia with Weight Gain ≥7% of Body Weight</span></span> </p>     <div class="scrollingtable">     <table width="94.72%">       <colgroup>       <col width="28%" />        <col width="35%" />        <col width="12%" />        <col width="25%" />       </colgroup>      <thead>        <tr class="First Last">         <th class="Toprule" align="left" valign="top"></th>        <th class="Botrule Toprule" align="left" valign="top">Treatment Arm</th>        <th class="Botrule Toprule" align="left" valign="top">Na</th>        <th class="Botrule Toprule" align="left" valign="top">Patients n (%)</th>        </tr>       </thead>       <tbody>        <tr class="First">         <td class="Botrule" rowspan="2" valign="middle"> <p class="First">Weight gain ≥7% of body weight</p> </td>        <td class="Botrule Toprule"> <p class="First">ABILIFY MAINTENA</p> </td>        <td class="Botrule Toprule"> <p class="First">144</p> </td>        <td class="Botrule Toprule"> <p class="First">31 (21.5)</p> </td>        </tr>        <tr class="Last">         <td class="Botrule Toprule"> <p class="First">Placebo</p> </td>        <td class="Botrule Toprule"> <p class="First">141</p> </td>        <td class="Botrule Toprule"> <p class="First">12 (8.5)</p> </td>        </tr>       </tbody>      </table>    </div>     <p style="border-left:1px solid;"> <span class="XmChange">a N = the total number of subjects who had a measurement at baseline and at least one post-baseline result.</span> </p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.6"></a>   <a name="section-5.6"></a>    <p></p>    <h2>5.6 Orthostatic Hypotension</h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange">ABILIFY MAINTENA may cause orthostatic hypotension, perhaps due to its α1-adrenergic receptor antagonism. In the short-term, placebo-controlled trial in adults with schizophrenia, the adverse event of presyncope was reported in 1/167 (0.6%) of patients treated with ABILFY MAINTENA, while syncope and orthostatic hypotension were each reported in 1/172 (0.6%) of patients treated with placebo. During the stabilization phase of the randomized-withdrawal (maintenance) study, orthostasis-related adverse events were reported in 4/576 (0.7%) of patients treated with ABILIFY MAINTENA, including abnormal orthostatic blood pressure (1/576, 0.2%), postural dizziness (1/576, 0.2%), presyncope (1/576, 0.2%) and orthostatic hypotension (1/576, 0.2%).</span> </p>    <p style="border-left:1px solid;"> <span class="XmChange">In the short-term placebo-controlled trial, there were no patients in either treatment group with a significant orthostatic change in blood pressure (defined as a decrease in systolic blood pressure ≥20 mmHg accompanied by an increase in heart rate ≥25 when comparing standing to supine values). During the stabilization phase of the randomized-withdrawal (maintenance) study, the incidence of significant orthostatic change in blood pressure was 0.2% (1/575).</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.7"></a>   <a name="section-5.7"></a>    <p></p>    <h2>5.7 Leukopenia, Neutropenia, and Agranulocytosis</h2>    <p class="First">In clinical trials and post-marketing experience, leukopenia and neutropenia have been reported temporally related to antipsychotic agents, including ABILIFY MAINTENA. Agranulocytosis has also been reported [<span class="Italics"><a href="#S6.1">see ADVERSE REACTIONS (6.1)</a></span>].</p>    <p>Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC)/absolute neutrophil count (ANC) and a history of drug-induced leukopenia/neutropenia. In patients with a history of a clinically significant low WBC /ANC or drug-induced leukopenia/neutropenia, perform a complete blood count (CBC) frequently during the first few months of therapy. In such patients, consider discontinuation of ABILIFY MAINTENA at the first sign of a clinically significant decline in WBC in the absence of other causative factors.</p>    <p>Monitor patients with clinically significant neutropenia for fever or other symptoms or signs of infection and treat promptly if such symptoms or signs occur. Discontinue ABILIFY MAINTENA in patients with severe neutropenia (absolute neutrophil count &lt;1000/mm3) and follow their WBC counts until recovery.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.8"></a>   <a name="section-5.8"></a>    <p></p>    <h2>5.8 Seizures</h2>    <p class="First">As with other antipsychotic drugs, use ABILIFY MAINTENA cautiously in patients with a history of seizures or with conditions that lower the seizure threshold. Conditions that lower the seizure threshold may be more prevalent in a population of 65&nbsp;years or older.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.9"></a>   <a name="section-5.9"></a>    <p></p>    <h2>5.9 Potential for Cognitive and Motor Impairment</h2>    <p class="First">ABILIFY MAINTENA, like other antipsychotics, may impair judgment, thinking, or motor skills. Instruct patients to avoid operating hazardous machinery, including automobiles, until they are reasonably certain that therapy with ABILIFY MAINTENA does not affect them adversely.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.10"></a>   <a name="section-5.10"></a>    <p></p>    <h2>5.10 Body Temperature Regulation</h2>    <p class="First">Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing ABILIFY MAINTENA for patients who will be experiencing conditions which may contribute to an elevation in core body temperature, (e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration).</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.11"></a>   <a name="section-5.11"></a>    <p></p>    <h2>5.11 Dysphagia</h2>    <p class="First">Esophageal dysmotility and aspiration have been associated with antipsychotic drug use, including ABILIFY MAINTENA. ABILIFY MAINTENA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia <span class="Italics">[see </span><span class="Italics"><a href="#S5.1">WARNINGS AND PRECAUTIONS (5.1)</a></span><span class="Italics">]</span>.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">6 ADVERSE REACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34084-4">   <a name="S6"></a>  <a name="section-6"></a>   <p></p>    <p class="First">The following adverse reactions are discussed in more detail in other sections of the labeling:</p>   <dl>    <dt>    •   </dt>    <dd>    Increased Mortality in Elderly Patients with Dementia - Related Psychosis Use     <span class="Italics">[see <a href="#BOX">BOXED WARNING</a> and </span>    <span class="Italics"><a href="#S5.1">WARNINGS AND PRECAUTIONS (5.1)</a></span>    <span class="Italics">]</span>    </dd>    <dt>    •   </dt>    <dd>    Cerebrovascular Adverse Reactions, Including Stroke in Elderly Patients with Dementia-Related Psychosis     <span class="Italics">[see <a href="#BOX">BOXED WARNING</a> and </span>    <span class="Italics"><a href="#S5.2">WARNINGS AND PRECAUTIONS (5.2)</a></span>    <span class="Italics">]</span>    </dd>    <dt>    •   </dt>    <dd>    Neuroleptic Malignant Syndrome     <span class="Italics">[see </span>    <span class="Italics"><a href="#S5.3">WARNINGS AND PRECAUTIONS (5.3)</a></span>    <span class="Italics">]</span>    </dd>    <dt>    •   </dt>    <dd>    Tardive Dyskinesia     <span class="Italics">[see </span>    <span class="Italics"><a href="#S5.4">WARNINGS AND PRECAUTIONS (5.4)</a></span>    <span class="Italics">]</span>    </dd>    <dt>    •   </dt>    <dd>    Metabolic Changes     <span class="Italics">[see </span>    <span class="Italics"><a href="#S5.5">WARNINGS AND PRECAUTIONS (5.5)</a></span>    <span class="Italics">]</span>    </dd>    <dt>    •   </dt>    <dd>    Orthostatic Hypotension     <span class="Italics">[see </span>    <span class="Italics"><a href="#S5.6">WARNINGS AND PRECAUTIONS (5.6)</a></span>    <span class="Italics">]</span>    </dd>    <dt>    •   </dt>    <dd>    Leukopenia, Neutropenia, and Agranulocytosis     <span class="Italics">[see </span>    <span class="Italics"><a href="#S5.7">WARNINGS AND PRECAUTIONS (5.7)</a></span>    <span class="Italics">]</span>    </dd>    <dt>    •   </dt>    <dd>    Seizures     <span class="Italics">[see </span>    <span class="Italics"><a href="#S5.8">WARNINGS AND PRECAUTIONS (5.8)</a></span>    <span class="Italics">]</span>    </dd>    <dt>    •   </dt>    <dd>    Potential for Cognitive and Motor Impairment     <span class="Italics">[see </span>    <span class="Italics"><a href="#S5.9">WARNINGS AND PRECAUTIONS (5.9)</a></span>    <span class="Italics">]</span>    </dd>    <dt>    •   </dt>    <dd>    Body Temperature Regulation     <span class="Italics">[see </span>    <span class="Italics"><a href="#S5.10">WARNINGS AND PRECAUTIONS (5.10)</a></span>    <span class="Italics">]</span>    </dd>    <dt>    •   </dt>    <dd>    Dysphagia     <span class="Italics">[see </span>    <span class="Italics"><a href="#S5.11">WARNINGS AND PRECAUTIONS (5.11)</a></span>    <span class="Italics">]</span>    </dd>   </dl>   <div class="Section" data-sectioncode="42229-5">    <a name="S6.1"></a>   <a name="section-6.1"></a>    <p></p>    <h2>6.1 Clinical Trials Experience</h2>    <p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_f792a95f-6496-4719-93f7-15f1c08c3b90"></a>    <a name="section-6.1.1"></a>     <p></p>     <p class="First"> <span class="Bold">Safety Database of ABILIFY MAINTENA and Oral Aripiprazole</span> </p>     <p>Oral aripiprazole has been evaluated for safety in 16,114 adult patients who participated in multiple-dose, clinical trials in schizophrenia and other indications, and who had approximately 8,578&nbsp;patient-years of exposure to oral aripiprazole. A total of 3,901 patients were treated with oral aripiprazole for at least 180&nbsp;days, 2,259 patients were treated with oral aripiprazole for at least 360&nbsp;days, and 933 patients continuing aripiprazole treatment for at least 720&nbsp;days.</p>     <p>ABILIFY MAINTENA has been evaluated for safety in 2,188 adult patients in clinical trials in schizophrenia, with approximately 2,646&nbsp;patient-years of exposure to ABILIFY MAINTENA. A total of 1,230 patients were treated with ABILIFY MAINTENA for at least 180&nbsp;days (at least 7 consecutive injections) and 935 patients treated with ABILIFY MAINTENA had at least 1&nbsp;year of exposure (at least 13 consecutive injections).</p>     <p>The conditions and duration of treatment with ABILIFY MAINTENA included double-blind and open-label studies. The safety data presented below are derived from the 12-week double-blind placebo-controlled study of ABILIFY MAINTENA in adult patients with schizophrenia.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_4faacb3d-c3f6-49d4-bb90-5522b136707d"></a>    <a name="section-6.1.2"></a>     <p></p>     <p class="First"> <span class="Bold">Adverse Reactions with ABILIFY MAINTENA</span> </p>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_66d3d17a-50c1-4eff-94cd-5f09d729db1a"></a>     <a name="section-6.1.2.1"></a>      <p></p>      <p class="First"> <span class="Italics">Most Commonly Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials in Schizophrenia </span> </p>      <p>Based on the placebo-controlled trial of ABILIFY MAINTENA in schizophrenia, the most commonly observed adverse reactions associated with the use of aripiprazole in patients (incidence of 5% or greater and aripiprazole incidence at least twice that for placebo) were increased weight (16.8% vs 7.0%), akathisia (11.4% vs 3.5%) , injection site pain (5.4% vs 0.6%) and sedation (5.4% vs 1.2%).</p>      <p> <span class="Italics">Commonly Reported Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials in Schizophrenia </span> </p>      <p>The following findings are based on the double-blind, placebo-controlled trial that compared ABILIFY MAINTENA 400 mg or 300 mg to placebo in patients with schizophrenia. Table 7 lists the adverse reactions reported in 2% or more of ABILIFY MAINTENA-treated subjects and at a greater proportion than in the placebo group.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_800d9ab3-b06c-4ce2-91a2-73b24ca3886f"></a>     <a name="section-6.1.2.2"></a>      <p></p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_b704d121-a83f-4dac-8947-93b7b359f423"></a>     <a name="section-6.1.2.3"></a>      <p></p>      <div class="scrollingtable">      <table width="432pt">        <colgroup>        <col width="33%" />         <col width="25%" />         <col width="33%" />        </colgroup>       <thead>         <tr class="First">          <th class="Botrule" align="justify" colspan="3" valign="middle"><span class="Bold"><span class="Italics"><span class="Underline"> <br /> </span></span>Table 7: Adverse Reactions in ≥ 2% of ABILIFY MAINTENA-Treated Adult Patients with Schizophrenia in a 12-Week Double-Blind, Placebo-Controlled Trial<span class="Sup"> a</span></span></th>         </tr>         <tr>          <th class="Toprule" align="left" valign="middle"></th>         <th class="Toprule" align="center" colspan="2" valign="middle"><span class="Bold">Percentage of Patients Reporting Reaction<span class="Sup">a</span></span></th>         </tr>         <tr>          <th align="justify" valign="middle"><span class="Bold">System Organ Class</span></th>         <th align="center" valign="middle"><span class="Bold">ABILIFY MAINTENA</span></th>         <th align="center" valign="middle"><span class="Bold">Placebo</span></th>         </tr>         <tr class="Last">          <th class="Botrule" align="justify" valign="middle"><span class="Bold"> Preferred Term</span></th>         <th class="Botrule" align="center" valign="middle"><span class="Bold">(n=167)</span></th>         <th class="Botrule" align="center" valign="middle"><span class="Bold">(n=172)</span></th>         </tr>        </thead>        <tbody>         <tr class="First">          <td align="justify" valign="middle"> <p class="First"> <span class="Bold">Gastrointestinal Disorders</span> </p> </td>         <td valign="middle"></td>         <td valign="middle"></td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> Constipation</p> </td>         <td align="center" valign="middle"> <p class="First">10</p> </td>         <td align="center" valign="middle"> <p class="First">7</p> </td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> Dry Mouth</p> </td>         <td align="center" valign="middle"> <p class="First">4</p> </td>         <td align="center" valign="middle"> <p class="First">2</p> </td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> Diarrhea </p> </td>         <td align="center" valign="middle"> <p class="First">3</p> </td>         <td align="center" valign="middle"> <p class="First">2</p> </td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> Vomiting</p> </td>         <td align="center" valign="middle"> <p class="First">3</p> </td>         <td align="center" valign="middle"> <p class="First">1</p> </td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> Abdominal Discomfort</p> </td>         <td align="center" valign="middle"> <p class="First">2</p> </td>         <td align="center" valign="middle"> <p class="First">1</p> </td>         </tr>         <tr>          <td valign="middle"> <p class="First"> <span class="Bold">General Disorders and Administration Site Conditions</span> </p> </td>         <td valign="middle"></td>         <td></td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> Injection Site Pain</p> </td>         <td align="center" valign="middle"> <p class="First">5</p> </td>         <td align="center" valign="middle"> <p class="First">1</p> </td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> <span class="Bold">Infections and Infestations</span> </p> </td>         <td valign="middle"></td>         <td valign="middle"></td>         </tr>         <tr>          <td valign="middle"> <p class="First"> Upper Respiratory Tract Infection</p> </td>         <td align="center" valign="middle"> <p class="First">4</p> </td>         <td align="center" valign="middle"> <p class="First">2</p> </td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> <span class="Bold">Investigations</span> </p> </td>         <td valign="middle"></td>         <td valign="middle"></td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> Increased Weight</p> </td>         <td align="center" valign="middle"> <p class="First">17</p> </td>         <td align="center" valign="middle"> <p class="First">7</p> </td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> Decreased Weight</p> </td>         <td align="center" valign="middle"> <p class="First">4</p> </td>         <td align="center" valign="middle"> <p class="First">2</p> </td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> <span class="Bold">Musculoskeletal And Connective Tissue Disorders</span> </p> </td>         <td valign="middle"></td>         <td valign="middle"></td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> Arthralgia</p> </td>         <td align="center" valign="middle"> <p class="First">4</p> </td>         <td align="center" valign="middle"> <p class="First">1</p> </td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> Back Pain</p> </td>         <td align="center" valign="middle"> <p class="First">4</p> </td>         <td align="center" valign="middle"> <p class="First">2</p> </td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> Myalgia</p> </td>         <td align="center" valign="middle"> <p class="First">4</p> </td>         <td align="center" valign="middle"> <p class="First">2</p> </td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> Musculoskeletal Pain</p> </td>         <td align="center" valign="middle"> <p class="First">3</p> </td>         <td align="center" valign="middle"> <p class="First">1</p> </td>         </tr>         <tr>          <td align="justify" colspan="2" valign="middle"> <p class="First"> <span class="Bold">Nervous System Disorders</span> </p> </td>         <td valign="middle"></td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> Akathisia</p> </td>         <td align="center" valign="middle"> <p class="First">11</p> </td>         <td align="center" valign="middle"> <p class="First">4</p> </td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> Sedation</p> </td>         <td align="center" valign="middle"> <p class="First">5</p> </td>         <td align="center" valign="middle"> <p class="First">1</p> </td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> Dizziness</p> </td>         <td align="center" valign="middle"> <p class="First">4</p> </td>         <td align="center" valign="middle"> <p class="First">2</p> </td>         </tr>         <tr>          <td align="justify" valign="middle"> <p class="First"> Tremor</p> </td>         <td align="center" valign="middle"> <p class="First">3</p> </td>         <td align="center" valign="middle"> <p class="First">1</p> </td>         </tr>         <tr>          <td valign="middle"> <p class="First"> <span class="Bold">Respiratory, Thoracic And Mediastinal</span> </p> </td>         <td valign="middle"></td>         <td valign="middle"></td>         </tr>         <tr>          <td class="Botrule" align="justify" valign="middle"> <p class="First"> Nasal Congestion</p> </td>         <td class="Botrule" align="center" valign="middle"> <p class="First">2</p> </td>         <td class="Botrule" align="center" valign="middle"> <p class="First">1</p> </td>         </tr>         <tr class="Last">          <td class="Toprule" align="center" colspan="3" valign="middle"> <p class="First"> <span class="Sup">a</span> This table does not include adverse reactions which had an incidence equal to or less than placebo.</p> </td>         </tr>        </tbody>       </table>     </div>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_48ea727b-fa79-4a99-8989-867d87c7e701"></a>     <a name="section-6.1.2.4"></a>      <p></p>      <p class="First"> <span class="Italics">Other Adverse Reactions Observed During the Clinical Trial Evaluation of ABILIFY MAINTENA </span> </p>      <p>The following listing does not include reactions: 1) already listed in previous tables or elsewhere in labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have significant clinical implications, or 5) which occurred at a rate equal to or less than placebo.</p>      <p>Reactions are categorized by body system according to the following definitions: <span class="Italics">frequent</span> adverse reactions are those occurring in at least 1/100 patients; <span class="Italics">infrequent</span> adverse reactions are those occurring in 1/100 to 1/1000 patients; <span class="Italics">rare</span> reactions are those occurring in fewer than 1/1000 patients:</p>      <p> <span class="Italics">Blood and Lymphatic System Disorders:</span><span class="Italics">rare - </span>thrombocytopenia </p>      <p> <span class="Italics">Cardiac Disorders:</span><span class="Italics">infrequent </span>- tachycardia, <span class="Italics">rare </span>- bradycardia, sinus tachycardia</p>      <p> <span class="Italics">Endocrine Disorders:</span><span class="Italics">rare - </span>hypoprolactinemia</p>      <p> <span class="Italics">Eye Disorders:</span><span class="Italics">infrequent - </span>vision blurred, oculogyric crisis </p>      <p> <span class="Italics">Gastrointestinal Disorders:</span><span class="Italics">infrequent </span>- abdominal pain upper, dyspepsia, nausea, <span class="Italics">rare </span>-swollen tongue</p>      <p> <span class="Italics">General Disorders and Administration Site Conditions:</span><span class="Italics">frequent -</span> fatigue, injection site reactions (including erythema, induration, pruritus, injection site reaction, swelling, rash, inflammation, hemorrhage), <span class="Italics">infrequent -</span> chest discomfort, gait disturbance, <span class="Italics">rare</span>-irritability, pyrexia </p>      <p> <span class="Italics">Hepatobiliary Disorders:</span><span class="Italics">rare </span>- drug induced liver injury</p>      <p> <span class="Italics">Immune System Disorders:</span><span class="Italics">rare </span>- drug hypersensitivity</p>      <p> <span class="Italics">Infections and Infestations:</span><span class="Italics">rare </span>- nasopharyngitis</p>      <p> <span class="Italics">Investigations:</span><span class="Italics">infrequent -</span> blood creatine phosphokinase increased, blood pressure decreased, hepatic enzyme increased, liver function test abnormal, electrocardiogram QT-prolonged, <span class="Italics">rare - </span>blood triglycerides decreased, blood cholesterol decreased, electrocardiogram T-wave abnormal </p>      <p> <span class="Italics">Metabolism and Nutrition Disorders:</span><span class="Italics">infrequent - </span>decreased appetite, obesity, hyperinsulinemia</p>      <p> <span class="Italics">Musculoskeletal and Connective Tissue Disorders:</span><span class="Italics">infrequent </span>- joint stiffness, muscle twitching, <span class="Italics">rare -</span> rhabdomyolysis</p>      <p> <span class="Italics">Nervous System Disorders:</span><span class="Italics">infrequent </span>- cogwheel rigidity, extrapyramidal disorder, hypersomnia, lethargy, <span class="Italics">rare</span>- bradykinesia, convulsion, dysgeusia, memory impairment, oromandibular dystonia</p>      <p> <span class="Italics">Psychiatric Disorders:</span><span class="Italics">frequent - </span>anxiety, insomnia restlessness, <span class="Italics">infrequent</span>- agitation, bruxism, depression, psychotic disorder, suicidal ideation, <span class="Italics">rare - </span>aggression, hypersexuality, panic attack </p>      <p> <span class="Italics">Renal and Urinary Disorders</span>: <span class="Italics">rare </span>- glycosuria, pollakiuria, urinary incontinence</p>      <p> <span class="Italics">Vascular Disorders:</span><span class="Italics">infrequent - </span>hypertension</p>      <p> <span class="Italics">Demographic Differences</span> </p>      <p>An examination of population subgroups was performed across demographic subgroup categories for adverse reactions experienced by at least 5% of aripiprazole IM depot subjects at least twice rate of the placebo (i.e., increased weight, akathisia, injection site pain, and sedation) in the double-blind placebo-controlled trial. This analysis did not reveal evidence of differences in safety differential adverse reaction incidence on the basis of age, gender, or race alone; however, there were few subjects ≥ 65 years of age.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_e92b90b5-95d2-4cf7-80bd-2055f4d49aad"></a>     <a name="section-6.1.2.5"></a>      <p></p>      <p class="First"> <span class="Italics">Injection Site Reactions of ABILIFY MAINTENA</span> </p>      <p>In the data from the short-term, double-blind, placebo-controlled trial with ABILIFY MAINTENA in patients with schizophrenia, the percent of patients reporting any injection site-related adverse reaction (all reported as injection site pain) was 5.4% for patients treated with gluteal administered ABILIFY MAINTENA and 0.6% for placebo. The mean intensity of injection pain reported by subjects using a visual analog scale (0=no pain to 100=unbearably painful) approximately one hour after injection was 7.1 (SD 14.5) for the first injection and 4.8 (SD 12.4) at the last visit in the double-blind, placebo-controlled phase.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_287cba90-483b-4b87-9efa-3c6a2eb4df5c"></a>     <a name="section-6.1.2.6"></a>      <p></p>      <p class="First"> <span class="Italics">Extrapyramidal Symptoms (EPS)</span> </p>      <p>In the short-term, placebo-controlled trial of ABILIFY MAINTENA in adults with schizophrenia, the incidence of reported EPS-related events, excluding events related to akathisia, for ABILIFY MAINTENA-treated patients was 9.6% vs. 5.2% for placebo. The incidence of akathisia-related events for ABILIFY MAINTENA-treated patients was 11.5% vs. 3.5% for placebo.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_930e37fb-f067-4398-b921-c5336a96d3f9"></a>     <a name="section-6.1.2.7"></a>      <p></p>      <p class="First"> <span class="Italics">Dystonia</span> </p>      <p>Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups. In the short-term, placebo-controlled trial of ABILIFY MAINTENA in adults with schizophrenia, the incidence of dystonia was 1.8% for ABILIFY MAINTENA vs. 0.6% for placebo.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_1e5966b7-d35f-44f1-86cc-e4297a098374"></a>     <a name="section-6.1.2.8"></a>      <p></p>      <p class="First"> <span class="Italics">Neutropenia</span> </p>      <p>In the short-term, placebo-controlled trial of ABILIFY MAINTENA in adults with schizophrenia, the incidence of neutropenia (absolute neutrophil count ≤1.5 thous/&micro;L) for ABILIFY MAINTENA-treated patients was 5.7% vs. 2.1% for placebo. An absolute neutrophil count of &lt;1 thous/&micro;L (i.e. 0.95 thous/&micro;L) was observed in only one patient on ABILIFY MAINTENA and resolved spontaneously without any associated adverse events [see WARNINGS AND PRECAUTIONS (5.7)]</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_f6a7d927-bf68-4087-8469-11b119b5ec3a"></a>     <a name="section-6.1.2.9"></a>      <p></p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_5203d9c9-02f0-4a14-a3a1-bcb3d9b51291"></a>     <a name="section-6.1.2.10"></a>      <p></p>      <p class="First"> <span class="Italics">Adverse Reactions Reported in Clinical Trials with Oral Aripiprazole</span> </p>      <p>The following is a list of additional adverse reactions that have been reported in clinical trials with oral aripiprazole and not reported above for Abilify Maintena: </p>      <p> <span class="Italics">Cardiac Disorders: </span>palpitations, cardiopulmonary failure, myocardial infarction, cardio-respiratory arrest, atrioventricular block, extrasystoles, angina pectoris, myocardial ischemia, atrial flutter, supraventricular tachycardia, ventricular tachycardia</p>      <p> <span class="Italics">Eye Disorders:</span> photophobia, diplopia, eyelid edema, photopsia</p>      <p> <span class="Italics">Gastrointestinal Disorders:</span> gastroesophageal reflux disease, swollen tongue, esophagitis, pancreatitis, stomach discomfort, toothache</p>      <p> <span class="Italics">General Disorders and Administration Site Conditions:</span> asthenia, peripheral edema, chest pain, face edema, angioedema, hypothermia, pain</p>      <p> <span class="Italics">Hepatobiliary Disorders:</span> hepatitis, jaundice</p>      <p> <span class="Italics">Immune System Disorders: </span> hypersensitivity</p>      <p> <span class="Italics">Injury, Poisoning, and Procedural Complications:</span> heat stroke</p>      <p> <span class="Italics">Investigations: </span>blood prolactin increased, blood urea increased, blood creatinine increased, blood bilirubin increased, blood lactate dehydrogenase increased, glycosylated hemoglobin increased</p>      <p> <span class="Italics">Metabolism and Nutrition Disorders: </span>anorexia, hyponatremia, hypoglycemia, polydipsia<span class="Underline">,</span> diabetic ketoacidosis</p>      <p> <span class="Italics">Musculoskeletal and Connective Tissue Disorders:</span> muscle rigidity, muscular weakness, muscle tightness, decreased mobility, rhabdomyolysis, musculoskeletal stiffness, pain in extremity, muscle spasms</p>      <p> <span class="Italics">Nervous System Disorders:</span> coordination abnormal, speech disorder, hypokinesia, hypotonia, myoclonus, akinesia, bradykinesia, choreoathetosis</p>      <p> <span class="Italics">Psychiatric Disorders:</span> loss of libido, suicide attempt, hostility, libido increased, anger, anorgasmia, delirium, intentional self injury, completed suicide, tic, homicidal ideation, catatonia, sleep walking</p>      <p> <span class="Italics">Renal and Urinary Disorders:</span> urinary retention, polyuria, nocturia</p>      <p> <span class="Italics">Reproductive System and Breast Disorders:</span> menstruation irregular, erectile dysfunction, amenorrhea, breast pain, gynecomastia, priapism</p>      <p> <span class="Italics">Respiratory, Thoracic, and Mediastinal Disorders: </span>nasal congestion, dyspnea, pharyngolaryngeal pain, cough</p>      <p> <span class="Italics">Skin and Subcutaneous Tissue Disorders: </span>rash (including erythematous, exfoliative, generalized, macular, maculopapular, papular rash; acneiform, allergic, contact, exfoliative, seborrheic dermatitis, neurodermatitis, and drug eruption), hyperhidrosis, pruritus, photosensitivity reaction, alopecia, urticaria</p>     </div>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S6.2"></a>   <a name="section-6.2"></a>    <p></p>    <h2>6.2 Postmarketing Experience</h2>    <p class="First">The following adverse reactions have been identified during post-approval use of oral aripiprazole or ABILIFY MAINTENA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: occurrences of allergic reaction (anaphylactic reaction, angioedema, laryngospasm, pruritus/urticaria, or oropharyngeal spasm) and blood glucose fluctuation.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">7 DRUG INTERACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34073-7">   <a name="S7"></a>  <a name="section-7"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S7.1"></a>   <a name="section-7.1"></a>    <p></p>    <h2>7.1 Drugs Having Clinically Important Interactions with ABILIFY MAINTENA</h2>    <p class="First"> <span class="Bold">Table 8: Clinically Important Drug Interactions with ABILIFY MAINTENA:</span> </p>    <div class="scrollingtable">    <table width="441.9pt">      <colgroup>      <col width="20%" />       <col width="37%" />       <col width="36%" />      </colgroup>     <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" valign="middle"> <p class="First"> <span class="Bold">Concomitant Drug Name or Drug Class</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" valign="middle"> <p class="First"> <span class="Bold">Clinical Rationale</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" valign="middle"> <p class="First"> <span class="Bold">Clinical Recommendation</span> </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="middle"> <p class="First">Strong CYP3A4 Inhibitors (e.g., ketoconazole) or strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine) </p> </td>       <td class="Botrule Lrule Rrule Toprule" valign="middle"> <p class="First">The concomitant use of oral aripiprazole with strong CYP 3A4 or CYP2D6 inhibitors increased the exposure of aripiprazole<br /> <span class="Italics">[see <a href="#S12.3">CLINICAL PHARMACOLOGY (12.3)</a>].</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" valign="middle"> <p class="First">With concomitant use of ABILIFY MAINTENA with a strong CYP3A4 inhibitor or CYP2D6 inhibitor for more than 14 days, reduce the ABILIFY MAINTENA dosage <br /> <span class="Italics">[see <a href="#S2.3">DOSAGE AND ADMINISTRATION (2.3)]. </a></span> </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="middle"> <p class="First">Strong CYP3A4 Inducers (e.g., carbamazepine)</p> </td>       <td class="Botrule Lrule Rrule Toprule" valign="middle"> <p class="First">The concomitant use of oral aripiprazole and carbamazepine decreased the exposure of aripiprazole <span class="Italics">[see <a href="#S12.3">CLINICAL PHARMACOLOGY (12.3)</a>].</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" valign="middle"> <p class="First">Avoid use of ABILIFY MAINTENA in combination with carbamazepine and other inducers of CYP3A4 for greater than 14&nbsp;days <span class="Italics">[see <a href="#_RefS2.3">DOSAGE AND ADMINISTRATION (2.3)</a>]</span>.</p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="middle"> <p class="First">Antihypertensive Drugs</p> </td>       <td class="Botrule Lrule Rrule Toprule" valign="middle"> <p class="First">Due to its alpha adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.</p> </td>       <td class="Botrule Lrule Rrule Toprule" valign="middle"> <p class="First">Monitor blood pressure and adjust dose accordingly <span class="Italics">[see <a href="#S5.6">WARNINGS AND PRECAUTIONS (5.6)</a>]. </span> </p> </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule Toprule" valign="middle"> <p class="First">Benzodiazepines (e.g., lorazepam)</p> </td>       <td class="Botrule Lrule Rrule Toprule" valign="middle"> <p class="First">The intensity of sedation was greater with the combination of oral aripiprazole and lorazepam as compared to that observed with aripiprazole alone. The orthostatic hypotension observed was greater with the combination as compared to that observed with lorazepam alone <span class="Italics">[see <a href="#S5.7">WARNINGS AND PRECAUTIONS (5.7)</a>].</span> </p> </td>       <td class="Botrule Lrule Rrule Toprule" valign="middle"> <p class="First">Monitor sedation and blood pressure. Adjust dose accordingly.</p> </td>       </tr>      </tbody>     </table>   </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S7.2"></a>   <a name="section-7.2"></a>    <p></p>    <h2>7.2 Drugs Having No Clinically Important Interactions with ABILIFY MAINTENA</h2>    <p class="First">Based on pharmacokinetic studies with oral aripiprazole, no dosage adjustment of ABILIFY MAINTENA is required when administered concomitantly with famotidine, valproate, lithium, lorazepam <span class="Italics">[see <span class="Underline"><a href="#S12.3">CLINICAL PHARMACOLOGY (12.3)</a></span>]</span>. </p>    <p>In addition, no dosage adjustment is necessary for substrates of CYP2D6 (e.g., dextromethorphan, fluoxetine, paroxetine, or venlafaxine), CYP2C9 (e.g., warfarin), CYP2C19 (e.g., omeprazole, warfarin), or CYP3A4 (e.g., dextromethorphan) when co-administered with ABILIFY MAINTENA. Additionally, no dosage adjustment is necessary for valproate, lithium, lamotrigine, lorazepam, or sertraline when co-administered with ABILIFY MAINTENA. <span class="Italics">[see <span class="Underline"><a href="#S12.3">CLINICAL PHARMACOLOGY (12.3)</a></span>]</span>.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">8 USE IN SPECIFIC POPULATIONS</a> <div class="Section toggle-content closed" data-sectioncode="43684-0">   <a name="S8"></a>  <a name="section-8"></a>   <p></p>    <div class="Section" data-sectioncode="42228-7">    <a name="S8.1"></a>   <a name="section-8.1"></a>    <p></p>    <h2>8.1 Pregnancy</h2>    <div class="Section" data-sectioncode="34077-8">     <a name="ID_ba36a102-bc37-4d18-a648-bbf466ff2173"></a>    <a name="section-8.1.1"></a>     <p></p>     <p class="First"> <span class="Italics">Pregnancy Category </span>C: </p>     <p>Pregnancy Exposure Registry</p>     <p>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ABILIFY during pregnancy. For more information contact the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit <a href="http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/">http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/</a>. </p>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_3d81336d-4242-4792-94bc-894d4a0254c7"></a>     <a name="section-8.1.1.1"></a>      <p></p>      <p class="First"> <span class="Italics">Risk Summary</span> </p>      <p>Neonates exposed to antipsychotic drugs (including ABILIFY MAINTENA) during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms. Adequate and well controlled studies with aripiprazole have not been conducted in pregnant women. </p>      <p>Animal reproduction studies were conducted with aripiprazole in rats and rabbits during organogenesis, and in rats during the pre-and post-natal period. Oral and intravenous aripiprazole administration during organogenesis in rats and/or rabbits at doses higher than the maximum recommended human dose (MRHD) produced fetal death, decreased fetal weight, undescended testicles, delayed skeletal ossification, skeletal abnormalities, and diaphragmatic hernia. Oral and intravenous aripiprazole administration during the pre- and post-natal period in rats at doses higher than the maximum recommended human dose (MRHD) produced prolonged gestation, stillbirths, decreased pup weight, and decreased pup survival. Administer ABILIFY during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>      <div class="Section" data-sectioncode="42229-5">       <a name="ID_3715d5fe-7ba0-46c7-8cc5-14c7e413242a"></a>      <a name="section-8.1.1.1.1"></a>       <p></p>       <p class="First"> <span class="Underline">Clinical Considerations</span> </p>       <div class="Section" data-sectioncode="42229-5">        <a name="ID_d0ef2b1d-eb9a-4307-ae97-c67ecb9f6b83"></a>       <a name="section-8.1.1.1.1.1"></a>        <p></p>        <p class="First"> <span class="Underline">Fetal/Neonatal Adverse Reactions</span> </p>        <p>Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder have been reported in neonates who were exposed to antipsychotic drugs (including oral aripiprazole) during the third trimester of pregnancy. These symptoms have varied in severity. Some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization. Monitor neonates exhibiting extrapyramidal or withdrawal symptoms. </p>       </div>      </div>      <div class="Section" data-sectioncode="42229-5">       <a name="ID_4a365746-e54d-47c6-a9b5-71a67e218a4f"></a>      <a name="section-8.1.1.1.2"></a>       <p></p>       <p class="First">Animal Data</p>       <p>In animal studies, aripiprazole demonstrated developmental toxicity, including possible teratogenic effects in rats and rabbits.</p>       <p>Pregnant rats were treated with oral doses of 3, 10, and 30 mg/kg/day (1, 3, and 10 times the maximum recommended human dose [MRHD] on a mg/m2 basis) of aripiprazole during the period of organogenesis. Gestation was slightly prolonged at 30 mg/kg/day. Treatment at the high dose of 30mg/kg/day caused a slight delay in fetal development (decreased fetal weight), undescended testes, and delayed skeletal ossification (also seen at 10 mg/kg/day). There were no adverse effects on embryofetal or pup survival. Delivered offspring had decreased body weights (10 and 30 mg/kg/day), and increased incidences of hepatodiaphragmatic nodules and diaphragmatic hernia at 30 mg/kg (the other dose groups were not examined for these findings). Postnatally, delayed vaginal opening was seen at 10 and 30 mg/kg/day and impaired reproductive performance (decreased fertility rate, corpora lutea, implants, live fetuses, and increased post-implantation loss, likely mediated through effects on female offspring) was seen at 30 mg/kg/day. Some maternal toxicity was seen at 30 mg/kg/day however, there was no evidence to suggest that these developmental effects were secondary to maternal toxicity. In pregnant rats receiving aripiprazole injection intravenously (3, 9, and 27 mg/kg/day) during the period of organogenesis, decreased fetal weight and delayed skeletal ossification were seen at the highest dose where it also caused maternal toxicity.</p>       <p>Pregnant rabbits were treated with oral doses of 10, 30, and 100 mg/kg/day (2, 3, and 11 times human exposure at MRHD based on AUC and 6, 19, and 65 times the MRHD based on mg/m2) of aripiprazole during the period of organogenesis. At the high dose of 100 mg/kg/day decreased maternal food consumption and increased abortions were seen as well as increased fetal mortality, decreased fetal weight (also seen at 30 mg/kg/day), and increased incidence of a skeletal abnormality (fused sternebrae) (also seen at 30 mg/kg/day).In pregnant rabbits receiving aripiprazole injection intravenously (3, 10, and 30 mg/kg/day) during the period of organogenesis, the highest dose, which caused pronounced maternal toxicity, resulted in decreased fetal weight, increased fetal abnormalities (primarily skeletal), and decreased fetal skeletal ossification. The fetal no-effect dose was 10 mg/kg, which is 5 times the human exposure at the MRHD based on AUC and is 6 times the MRHD based on mg/m<span class="Sup">2</span>.In a study in which rats were treated peri- and post-natally with oral doses of 3, 10, and 30 mg/kg/day (1, 3, and 10 times the MRHD on a mg/m<span class="Sup">2</span> basis) of aripiprazole from gestation day 17 through day 21 postpartum, slight maternal toxicity, slightly prolonged gestation, increased stillbirths and decreases in pup weight (persisting into adulthood) and survival were seen at 30mg/kg/day.In rats receiving aripiprazole injection intravenously (3, 8, and 20 mg/kg/day) from day 6 of gestation through day 20 postpartum, increased stillbirths were seen at 8 and 20 mg/kg, and decreases in early postnatal pup weight and survival were seen at 20 mg/kg. These doses produced some maternal toxicity. There were no effects on postnatal behavioral and reproductive development.</p>      </div>     </div>    </div>   </div>   <div class="Section" data-sectioncode="34080-2">    <a name="S8.3"></a>   <a name="section-8.2"></a>    <p></p>    <h2>8.3 Nursing Mothers</h2>    <p class="First">ABILIFY is present in human breast milk. Because of the potential for serious adverse reactions in nursing infants from ABILIFY, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>   </div>   <div class="Section" data-sectioncode="34081-0">    <a name="S8.4"></a>   <a name="section-8.3"></a>    <p></p>    <h2>8.4 Pediatric Use</h2>    <p class="First">ABILIFY MAINTENA has not been studied in children 18 years of age or younger. However, juvenile animal studies have been conducted in rats and dogs.</p>    <p> <span class="Bold">Juvenile Animal Studies</span> </p>    <p>Aripiprazole in juvenile rats caused mortality, CNS clinical signs, impaired memory and learning, and delayed sexual maturation when administered at oral doses of 10, 20, 40mg/kg/day from weaning (21 days old) through maturity (80 days old). At 40mg/kg/day, mortality, decreased activity, splayed hind limbs, hunched posture, ataxia, tremors and other CNS signs were observed in both genders. In addition, delayed sexual maturation was observed in males. At all doses and in a dose-dependent manner, impaired memory and learning, increased motor activity, and histopathology changes in the pituitary (atrophy), adrenals (adrenocortical hypertrophy), mammary glands (hyperplasia and increased secretion), and female reproductive organs (vaginal mucification, endometrial atrophy, decrease in ovarian corpora lutea) were observed. The changes in female reproductive organs were considered secondary to the increase in prolactin serum levels. A No Observed Adverse Effect Level (NOAEL) could not be determined and, at the lowest tested dose of 10mg/kg/day, there is no safety margin relative to the systemic exposures (AUC0-24) for aripiprazole or its major active metabolite in adolescents at the maximum recommended pediatric dose of 15 mg/day. All drug-related effects were reversible after a 2-month recovery period, and most of the drug effects in juvenile rats were also observed in adult rats from previously conducted studies.</p>    <p>Aripiprazole in juvenile dogs (2 months old) caused CNS clinical signs of tremors, hypoactivity, ataxia, recumbency and limited use of hind limbs when administered orally for 6 months at 3, 10, 30 mg/kg/day. Mean body weight and weight gain were decreased up to 18% in females in all drug groups relative to control values. A NOAEL could not be determined and, at the lowest tested dose of 3mg/kg/day, there is no safety margin relative to the systemic exposures (AUC0-24) for aripiprazole or its major active metabolite in adolescents at the maximum recommended pediatric dose of 15 mg/day. All drug-related effects were reversible after a 2-month recovery period.</p>   </div>   <div class="Section" data-sectioncode="34082-8">    <a name="S8.5"></a>   <a name="section-8.4"></a>    <p></p>    <h2>8.5 Geriatric Use</h2>    <p class="First">Clinical studies of ABILIFY did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience and pharmacokinetic data [<span class="Italics">see </span><span class="Italics"><a href="#S12.3">CLINICAL PHARMACOLOGY (12.3</a></span><span class="Italics">)]</span> have not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>    <p>In single-dose and multiple-dose pharmacokinetic studies, there was no detectable age effect in the population pharmacokinetic analysis of oral aripiprazole in schizophrenia patients <span class="Italics">[see <a href="#S12.3">CLINICAL PHARMACOLOGY (12.3)</a>]</span>. No dosage adjustments are recommended based on age alone. ABILIFY MAINTENA is not approved for the treatment of patients with psychosis associated with<span class="Bold"></span>Alzheimer’s disease <span class="Italics">[see also <a href="#_top">BOXED WARNING</a> and <a href="#S5.1">WARNINGS AND PRECAUTIONS (5.1)</a>].</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S8.6"></a>   <a name="section-8.5"></a>    <p></p>    <h2>8.6 CYP2D6 Poor Metabolizers</h2>    <p class="First">Dosage adjustment is recommended in known CYP2D6 poor metabolizers due to high aripiprazole concentrations. Approximately 8% of Caucasians and 3–8% of Black/African Americans cannot metabolize CYP2D6 substrates and are classified as poor metabolizers (PM) <span class="Italics">[see <span class="Underline"><a href="#_RefS2.3">DOSAGE AND ADMINISTRATION (2.3)</a></span>&nbsp;and <span class="Underline"><a href="#_RefS12.3">CLINICAL PHARMACOLOGY (12.3)</a></span>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_d0836ed0-24f0-4542-b1e4-d90daab6993c"></a>   <a name="section-8.6"></a>    <p></p>    <h2>8.7 Hepatic and Renal Impairment </h2>    <p class="First">No dosage adjustment for ABILIFY MAINTENA is required on the basis of a patient’s hepatic function (mild to severe hepatic impairment, Child-Pugh score between 5 and 15), or renal function (mild to severe renal impairment, glomerular filtration rate between 15 and 90 mL/minute) <span class="Italics">[see <a href="#S12.3">CLINICAL PHARMACOLOGY (12.3)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_07ed5341-47bd-4937-9a26-a7ac187e39ab"></a>   <a name="section-8.7"></a>    <p></p>    <h2>8.8 Other Specific Populations </h2>    <p class="First">No dosage adjustment for ABILIFY MAINTENA is required on the basis of a patient’s sex, race, or smoking status <span class="Italics">[see <a href="#S12.3">CLINICAL PHARMACOLOGY (12.3)</a>]</span>.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">10 OVERDOSAGE</a> <div class="Section toggle-content closed" data-sectioncode="34088-5">   <a name="S10"></a>  <a name="section-9"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S10.1"></a>   <a name="section-9.1"></a>    <p></p>    <h2>10.1 Human Experience</h2>    <p class="First">The largest known case of acute ingestion with a known outcome involved 1260&nbsp;mg of oral aripiprazole (42 times the maximum recommended daily dose) in a patient who fully recovered.</p>    <p>Common adverse reactions (reported in at least 5% of all overdose cases) reported with oral aripiprazole overdosage (alone or in combination with other substances) include vomiting, somnolence, and tremor. Other clinically important signs and symptoms observed in one or more patients with aripiprazole overdoses (alone or with other substances) include acidosis, aggression, aspartate aminotransferase increased, atrial fibrillation, bradycardia, coma, confusional state, convulsion, blood creatine phosphokinase increased, depressed level of consciousness, hypertension, hypokalemia, hypotension, lethargy, loss of consciousness, QRS complex prolonged, QT prolonged, pneumonia aspiration, respiratory arrest, status epilepticus, and tachycardia.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S10.2"></a>   <a name="section-9.2"></a>    <p></p>    <h2>10.2 Management of Overdosage</h2>    <p class="First">In case of overdosage, call the Poison Control Center immediately at 1-800-222-1222.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">11 DESCRIPTION</a> <div class="Section toggle-content closed" data-sectioncode="34089-3">   <a name="S11"></a>  <a name="section-10"></a>   <p></p>    <p class="First">Aripiprazole is an atypical antipsychotic which is present in ABILIFY MAINTENA as its monohydrate polymorphic form. Aripiprazole monohydrate is 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl] butoxy]-3,4 dihydrocarbostyril monohydrate. The empirical formula is C<span class="Sub">23</span>H<span class="Sub">27</span>Cl<span class="Sub">2</span>N<span class="Sub">3</span>O<span class="Sub">2•</span>H<span class="Sub">2</span>O and its molecular weight is 466.40. The chemical structure is:</p>   <div class="Figure">    <a name="id1935"></a>   <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Chemical%20Structure%2Ejpg" alt="Chemical Structure" />  </div>   <p>ABILIFY MAINTENA (aripiprazole) is an extended-release injectable suspension available in 400-mg or 300-mg strength pre-filled dual chamber syringes and 400-mg or 300-mg strength vials. The labeled strengths are calculated based on the anhydrous form (aripiprazole). Inactive ingredients (per administered dose) for 400 mg and 300 mg strength products, respectively, include carboxymethyl cellulose sodium (16.64 mg and 12.48 mg), mannitol (83.2 mg and 62.4 mg), sodium phosphate monobasic monohydrate (1.48 mg and 1.11 mg) and sodium hydroxide (pH adjuster). </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">12 CLINICAL PHARMACOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="34090-1">   <a name="S12"></a>  <a name="section-11"></a>   <p></p>    <div class="Section" data-sectioncode="43679-0">    <a name="S12.1"></a>   <a name="section-11.1"></a>    <p></p>    <h2>12.1 Mechanism of Action</h2>    <p class="First">The mechanism of action of aripiprazole in the treatment of schizophrenia is unknown.</p>    <p>However, the efficacy of aripiprazole may be mediated through a combination of partial agonist activity at D<span class="Sub">2</span> and 5-HT<span class="Sub">1A</span> receptors and antagonist activity at 5-HT<span class="Sub">2A</span> receptors. Actions at receptors other than D<span class="Sub">2</span>, 5-HT<span class="Sub">1A</span>, and 5-HT<span class="Sub">2A</span> may explain some of the other adverse reactions of aripiprazole (e.g., the orthostatic hypotension observed with aripiprazole may be explained by its antagonist activity at adrenergic alpha<span class="Sub">1</span> receptors).</p>   </div>   <div class="Section" data-sectioncode="43681-6">    <a name="S12.2"></a>   <a name="section-11.2"></a>    <p></p>    <h2>12.2 Pharmacodynamics</h2>    <p class="First">Aripiprazole exhibits high affinity for dopamine D<span class="Sub">2</span> and D<span class="Sub">3</span>, serotonin 5-HT<span class="Sub">1A</span> and 5-HT<span class="Sub">2A</span> receptors (K<span class="Sub">i</span> values of 0.34&nbsp;nM, 0.8&nbsp;nM, 1.7&nbsp;nM, and 3.4&nbsp;nM, respectively), moderate affinity for dopamine D<span class="Sub">4</span>, serotonin 5-HT<span class="Sub">2C</span> and 5-HT<span class="Sub">7</span>, alpha<span class="Sub">1</span>-adrenergic and histamine H<span class="Sub">1</span> receptors (K<span class="Sub">i</span> values of 44&nbsp;nM, 15&nbsp;nM, 39&nbsp;nM, 57&nbsp;nM, and 61&nbsp;nM, respectively), and moderate affinity for the serotonin reuptake site (K<span class="Sub">i</span>=98&nbsp;nM). Aripiprazole has no appreciable affinity for cholinergic muscarinic receptors (IC<span class="Sub">50</span>&gt;1000&nbsp;nM). Aripiprazole functions as a partial agonist at the dopamine D<span class="Sub">2</span> and the serotonin 5-HT<span class="Sub">1A</span> receptors, and as an antagonist at serotonin 5-HT<span class="Sub">2A</span> receptor.</p>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_6c792d95-3b1d-4c58-bf60-5108f8a6a3cb"></a>    <a name="section-11.2.1"></a>     <p></p>     <p class="First"> <span class="Italics">Alcohol</span> </p>     <p>There was no significant difference between oral aripiprazole co-administered with ethanol and placebo co-administered with ethanol on performance of gross motor skills or stimulus response in healthy subjects. As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY MAINTENA.</p>    </div>   </div>   <div class="Section" data-sectioncode="43682-4">    <a name="S12.3"></a>   <a name="section-11.3"></a>    <p></p>    <h2>12.3 Pharmacokinetics</h2>    <p class="First">ABILIFY MAINTENA activity is presumably primarily due to the parent drug, aripiprazole, and to a lesser extent, to its major metabolite, dehydro-aripiprazole, which has been shown to have affinities for D<span class="Sub">2</span> receptors similar to the parent drug and represents about 29% of the parent drug exposure in plasma.</p>    <p>Aripiprazole absorption into the systemic circulation is slow and prolonged following intramuscular injection due to low solubility of aripiprazole particles. Following a single intramuscular dose, the plasma concentrations of aripiprazole gradually rise and after multiple dose administrations, reach maximum plasma concentrations at a median T<span class="Sub">max</span> of 5-7&nbsp;days. The mean aripiprazole terminal elimination half-life was 29.9&nbsp;days and 46.5&nbsp;days after every 4-week injection of ABILIFY MAINTENA 300&nbsp;mg and 400&nbsp;mg, respectively, and steady state concentrations were attained by the fourth dose. Approximate dose-proportional increases in aripiprazole and dehydro-aripiprazole concentrations and AUC parameters were observed after every four&nbsp;week ABILIFY MAINTENA injections of 300&nbsp;mg and 400&nbsp;mg.</p>    <p>Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4. Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation.</p>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_16b245e2-3bae-49a7-8644-c7ea24305ae9"></a>    <a name="section-11.3.1"></a>     <p></p>     <p class="First"> <span class="Bold"><span class="Underline">Drug Interaction Studies</span></span> </p>     <p>No specific drug interaction studies have been performed with ABILIFY MAINTENA. The information below is obtained from studies with oral aripiprazole.</p>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_1ad7a19b-25b5-4ae2-889f-43734f88a54e"></a>     <a name="section-11.3.1.1"></a>      <p></p>      <p class="First">Effects of other drugs on the exposures of aripiprazole and dehydro-aripiprazole are summarized in Figure 19 and Figure 20, respectively. Based on simulation, a 4.5-fold increase in mean Cmax and AUC values at steady-state is expected when extensive metabolizers of CYP2D6 are administered with both strong CYP2D6 and CYP3A4 inhibitors. After oral administration, a 3-fold increase in mean Cmax and AUC values at steady-state is expected in poor metabolizers of CYP2D6 administered with strong CYP3A4 inhibitors.</p>      <dl>       <dt>       &nbsp;      </dt>       <dd>        <span class="Bold">Figure 19: The effects of other drugs on aripiprazole pharmacokinetics</span>       </dd>      </dl>      <div class="Figure">       <a name="id2114159149"></a>      <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%2019%2Ejpg" alt="Figure19" />     </div>      <dl>       <dt>       &nbsp;      </dt>       <dd>        <span class="Bold">Figure 20: The effects of other drugs on dehydro-aripiprazole pharmacokinetics </span>       </dd>      </dl>      <div class="Figure">       <a name="id-1732847171"></a>      <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%2020%2Ejpg" alt="Figure 20" />     </div>      <p>The effects of ABILIFY on the exposures of other drugs are summarized in Figure 21. A population PK analysis in patients with major depressive disorder showed no substantial change in plasma concentrations of fluoxetine (20 mg/day or 40 mg/day), paroxetine CR (37.5 mg/day or 50 mg/day), or sertraline (100 mg/day or 150 mg/day) dosed to steady-state. The steady-state plasma concentrations of fluoxetine and norfluoxetine increased by about 18% and 36%, respectively, and concentrations of paroxetine decreased by about 27%. The steady-state plasma concentrations of sertraline and desmethylsertraline were not substantially changed when these antidepressant therapies were coadministered with aripiprazole.</p>      <dl>       <dt>       &nbsp;      </dt>       <dd>        <span class="Bold">Figure 21: The effects of ABILIFY on pharmacokinetics of other drugs </span>       </dd>      </dl>      <div class="Figure">       <a name="id-471289411"></a>      <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%2021%2Ejpg" alt="Figure 21" />     </div>     </div>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_df68fe6d-ec64-404d-b62e-3bd66880f355"></a>    <a name="section-11.3.2"></a>     <p></p>     <p class="First"> <span class="Bold"><span class="Underline">Studies in Specific Populations</span></span> </p>     <p>No specific pharmacokinetic studies have been performed with ABILIFY MAINTENA in specific populations. All the information is obtained from studies with oral aripiprazole.</p>     <p>Exposures of aripiprazole and dehydro-aripiprazole in specific populations are summarized in Figure 22 and Figure 23, respectively. In addition, in pediatric patients (10 to 17 years of age) administered with Abilify (20 mg to 30 mg), the body weight corrected aripiprazole clearance was similar to the adults. </p>     <p> <span class="Bold">Figure 22 Effects of intrinsic factors on aripiprazole pharmacokinetics </span> </p>     <div class="Figure">      <a name="id-290750811"></a>     <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%2022%2Ejpg" alt="Figure 22" />    </div>     <p> <span class="Bold">Figure 23: Effects of intrinsic factors on dehydro-aripiprazole pharmacokinetics:</span> </p>     <div class="Figure">      <a name="id-1992083982"></a>     <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%2023%2Ejpg" alt="Figure 23" />    </div>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">13 NONCLINICAL TOXICOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="43680-8">   <a name="S13"></a>  <a name="section-12"></a>   <p></p>    <div class="Section" data-sectioncode="34083-6">    <a name="S13.1"></a>   <a name="section-12.1"></a>    <p></p>    <h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_2a5c2bff-cfaf-48b7-9ebb-e1bbfe5a74ff"></a>    <a name="section-12.1.1"></a>     <p></p>     <p class="First"> <span class="Italics">Carcinogenesis</span> </p>     <p>Lifetime carcinogenicity studies were conducted in ICR mice and in Sprague-Dawley (SD) and F344 rats. Aripiprazole was administered for 2&nbsp;years in the diet at doses of 1&nbsp;mg/kg/day, 3&nbsp;mg/kg/day, 10&nbsp;mg/kg/day, and 30&nbsp;mg/kg/day to ICR mice and 1&nbsp;mg/kg/day, 3&nbsp;mg/kg/day, and 10&nbsp;mg/kg/day to F344 rats (0.2 times to 5 times and 0.3 times to 3 times the oral maximum recommended human dose [MRHD] of 30&nbsp;mg/day based on&nbsp;mg/m<span class="Sup">2</span> body surface area, respectively). In addition, SD rats were dosed orally for 2&nbsp;years at 10&nbsp;mg/kg/day, 20&nbsp;mg/kg/day, 40&nbsp;mg/kg/day, and 60&nbsp;mg/kg/day (3 times to 19 times the oral MRHD of 30&nbsp;mg/day based on&nbsp;mg/m<span class="Sup">2</span> body surface area). Aripiprazole did not induce tumors in male mice or rats. In female mice, the incidences of pituitary gland adenomas and mammary gland adenocarcinomas and adenoacanthomas were increased at dietary doses of 3&nbsp;mg/kg/day to 30&nbsp;mg/kg/day (0.1 times to approximately 1 times human exposure at the oral MRHD of 30&nbsp;mg/day based on AUC and 0.5 times to 5 times the oral MRHD of 30&nbsp;mg/day based on&nbsp;mg/m<span class="Sup">2</span> body surface area). In female rats, the incidence of mammary gland fibroadenomas was increased at a dietary dose of 10 mg/kg/day (0.1 times human exposure at the oral MRHD of 30&nbsp;mg/day based on AUC and 3 times the oral MRHD of 30&nbsp;mg/day based on&nbsp;mg/m<span class="Sup">2</span> body surface area); and the incidences of adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas were increased at an oral dose of 60&nbsp;mg/kg/day (14 times human exposure at the oral MRHD of 30&nbsp;mg/day based on AUC and 19 times the oral MRHD of 30&nbsp;mg/day based on&nbsp;mg/m<span class="Sup">2</span> body surface area).</p>     <p>Proliferative changes in the pituitary and mammary gland of rodents have been observed following chronic administration of other antipsychotic agents and are considered prolactin-mediated. Serum prolactin was not measured in the aripiprazole carcinogenicity studies. However, increases in serum prolactin levels were observed in female mice in a 13-week dietary study at the doses associated with mammary gland and pituitary tumors. Serum prolactin was not increased in female rats in 4-week and 13-week dietary studies at the dose associated with mammary gland tumors. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is unknown.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_c283af02-1b94-4cf3-bd16-95dbbbd59112"></a>    <a name="section-12.1.2"></a>     <p></p>     <p class="First"> <span class="Italics">Mutagenesis</span> </p>     <p>Aripiprazole was not mutagenic when tested in the <span class="Italics">in vitro</span> bacterial mutation assay, the <span class="Italics">in vitro</span> bacterial DNA repair assay, and the <span class="Italics">in vitro</span> mouse lymphoma gene mutation assay. The clastogenic potential of aripiprazole was tested in the <span class="Italics">in vitro</span> chromosomal aberration assay in Chinese hamster lung (CHL) cells, the <span class="Italics">in vivo</span> micronucleus assay in mice, and the unscheduled DNA synthesis assay in rats. Aripiprazole and its metabolite (2,3-DCPP) were clastogenic in the <span class="Italics">in vitro</span> chromosomal aberration assay in CHL cells both in the presence and absence of metabolic activation. The metabolite, 2,3-DCPP, produced increases in numerical aberrations in the <span class="Italics">in vitro</span> assay in CHL cells in the absence of metabolic activation. A positive response was obtained in the oral <span class="Italics">in vivo</span> micronucleus assay in mice; however, the response was due to a mechanism not considered relevant to humans.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_d5ecabc8-68cc-473e-96d3-09bd4666754f"></a>    <a name="section-12.1.3"></a>     <p></p>     <p class="First"> <span class="Italics">Impairment of Fertility</span> </p>     <p>Female rats were treated with oral doses of 2&nbsp;mg/kg/day, 6&nbsp;mg/kg/day, and 20&nbsp;mg/kg/day (0.6 times, 2 times, and 6 times the oral maximum recommended human dose [MRHD] of 30&nbsp;mg/day on a&nbsp;mg/m<span class="Sup">2</span> body surface area) of aripiprazole from 2&nbsp;weeks prior to mating through day 7 of gestation. Estrus cycle irregularities and increased corpora lutea were seen at all doses, but no impairment of fertility was seen. Increased pre-implantation loss was seen at 6&nbsp;mg/kg and 20&nbsp;mg/kg and decreased fetal weight was seen at 20&nbsp;mg/kg.</p>     <p>Male rats were treated with oral doses of 20&nbsp;mg/kg/day, 40&nbsp;mg/kg/day, and 60&nbsp;mg/kg/day (6 times, 13 times, and 19 times the oral MRHD of 30&nbsp;mg/day on a&nbsp;mg/m<span class="Sup">2</span> body surface area) of aripiprazole from 9&nbsp;weeks prior to mating through mating. Disturbances in spermatogenesis were seen at 60&nbsp;mg/kg and prostate atrophy was seen at 40&nbsp;mg/kg and 60&nbsp;mg/kg, but no impairment of fertility was seen.</p>    </div>   </div>   <div class="Section" data-sectioncode="34091-9">    <a name="S13.2"></a>   <a name="section-12.2"></a>    <p></p>    <h2>13.2 Animal Toxicity and/or Pharmacology</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_6d52323b-d3ac-426b-ac12-f7507b9615b2"></a>    <a name="section-12.2.1"></a>     <p></p>     <p class="First"> <span class="Italics">Oral Aripiprazole</span> </p>     <p>Aripiprazole produced retinal degeneration in albino rats in a 26-week chronic toxicity study at a dose of 60&nbsp;mg/kg and in a 2-year carcinogenicity study at doses of 40&nbsp;mg/kg and 60&nbsp;mg/kg. The 40&nbsp;mg/kg and 60&nbsp;mg/kg doses are 13 times and 19 times the oral maximum recommended human dose (MRHD) of 30&nbsp;mg/day based on&nbsp;mg/m<span class="Sup">2</span> body surface area and 7 times to 14 times human exposure at the oral MRHD based on AUC. Evaluation of the retinas of albino mice and of monkeys did not reveal evidence of retinal degeneration. Additional studies to further evaluate the mechanism have not been performed. The relevance of this finding to human risk is unknown.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_786287fa-9a2b-42e8-89a3-d02656a7f729"></a>    <a name="section-12.2.2"></a>     <p></p>     <p class="First"> <span class="Italics">Intramuscular Aripiprazole</span> </p>     <p>The toxicological profile for aripiprazole administered to experimental animals by intramuscular injection is generally similar to that seen following oral administration at comparable plasma levels of the drug. With intramuscular injection, however, injection-site tissue reactions are observed that consist of localized inflammation, swelling, scabbing and foreign-body reactions to deposited drug. These effects gradually resolved with discontinuation of dosing.</p>     <p>After 26&nbsp;weeks of treatment in rats, the no-observed-adverse-effect level (NOAEL) was 50&nbsp;mg/kg in male rats and 100&nbsp;mg/kg in female rats, which are approximately 1 and 2 times, respectively, the maximum recommended human 400&nbsp;mg dose of aripiprazole extended-release injectable suspension on a&nbsp;mg/m<span class="Sup">2</span> body surface area. At the NOAEL in rats, the AUC<span class="Sub">7d</span> values were 14.4&nbsp;&micro;g∙h/mL in males and 104.1&nbsp;&micro;g∙h/mL in females. In dogs at 52&nbsp;weeks of treatment at the NOAEL of 40&nbsp;mg/kg, which is approximately 3 times the MRHD (400&nbsp;mg) on a&nbsp;mg/m<span class="Sup">2</span> body surface area, the AUC<span class="Sub">7d </span>values were approximately 59&nbsp;&micro;g∙h/mL in males and 44&nbsp;&micro;g∙h/mL in females. In patients at the MRHD of 400&nbsp;mg, the AUCτ (0-28&nbsp;days) was 163&nbsp;&micro;g∙h/mL. For comparison to this human AUC, extrapolating the animal AUC<span class="Sub">7d</span> values to an AUC<span class="Sub">28d</span> results in AUC<span class="Sub">28d</span> values of approximately 58 and 416&nbsp;&micro;g∙h/mL for male and female rats, respectively, and 236 and 175&nbsp;&micro;g∙h/mL for male and female dogs, respectively.</p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">14 CLINICAL STUDIES</a> <div class="Section toggle-content closed" data-sectioncode="34092-7">   <a name="S14"></a>  <a name="section-13"></a>   <p></p>    <p class="First">The efficacy of ABILIFY MAINTENA for treatment of schizophrenia was established in:</p>   <dl>    <dt>    &nbsp;   </dt>    <dd>    • One short-term (12-week), randomized, double-blind, placebo-controlled trial in acutely relapsed adults, Protocol 31-12-291 (Study 1)   </dd>    <dt>    &nbsp;   </dt>    <dd>    • One longer-term, double-blind, placebo-controlled, randomized-withdrawal (maintenance) trial in adults, Protocol 31-07-246 (Study 2).   </dd>   </dl>   <p> <span class="Italics">Short-Term Efficacy</span> </p>   <p>In the short-term (12-week), randomized, double-blind, placebo-controlled trial in acutely relapsed adults (Study 1), the primary measure used for assessing psychiatric signs and symptoms was the Positive and Negative Syndrome Scale (PANSS). The PANSS is a 30 item scale that measures positive symptoms of schizophrenia (7 items), negative symptoms of schizophrenia (7 items), and general psychopathology (16 items), each rated on a scale of 1 (absent) to 7 (extreme); total PANSS scores range from 30 to 210. The primary endpoint was the change from baseline in PANSS total score to week 10.</p>   <p>The inclusion criteria for this short-term trial included adult inpatients who met DSM-IV-TR criteria for schizophrenia. In addition, all patients entering the trial must have experienced an acute psychotic episode as defined by both PANSS Total Score ≥ 80 and a PANSS score of &gt; 4 on each of four specific psychotic symptoms (conceptual disorganization, hallucinatory behavior, suspiciousness/persecution, unusual thought content) at screening and baseline. The key secondary endpoint was the change from baseline in Clinical Global Impression-Severity (CGI-S) assessment scale to week 10. The CGI-S rates the severity of mental illness on a scale of 1 (normal) to 7 (among the most extremely ill) based on the total clinical experience of the rater in treating patients with schizophrenia. Patients had a mean PANSS total score of 103 (range 82 to 144) and a CGI-S score of 5.2 (markedly ill) at entry.</p>   <p>In this 12-week study (n=339) comparing ABILIFY MAINTENA (n=167) to placebo (n=172), patients were administered 400 mg ABILIFY MAINTENA or placebo on days 0, 28, and 56. The dose could be adjusted down and up within the range of 400 to 300 mg on a one time basis. ABILIFY MAINTENA was superior to placebo in improving the PANSS total score at the end of week 10 (see Table 9). </p>   <div class="scrollingtable">   <table width="446.4pt">     <colgroup>     <col width="15%" />      <col width="24%" />      <col width="18%" />      <col width="20%" />      <col width="23%" />     </colgroup>    <tbody class="Headless">      <tr class="First">       <td colspan="5" valign="middle"> <p class="First"> <span class="Bold">Table 9: Schizophrenia Short-term Study</span> </p> </td>      </tr>      <tr>       <td class="Botrule Toprule" rowspan="2"> <p class="First"> <span class="Bold">Study Number</span> </p> </td>      <td class="Botrule Toprule" rowspan="2"> <p class="First"> <span class="Bold">Treatment Group</span> </p> </td>      <td class="Botrule Toprule" colspan="3" valign="middle"> <p class="First"> <span class="Bold">Primary Efficacy Measure: PANSS Total Score</span> </p> </td>      </tr>      <tr>       <td class="Botrule Toprule" valign="middle"> <p class="First"> <span class="Bold">Mean Baseline Score (SD)</span> </p> </td>      <td class="Botrule Toprule" valign="middle"> <p class="First"> <span class="Bold">LS Mean Change from Baseline (SE)</span> </p> </td>      <td class="Botrule Toprule" valign="middle"> <p class="First"> <span class="Bold">Placebo-subtracted Difference<span class="Sup">a</span> (95% CI)</span> </p> </td>      </tr>      <tr>       <td class="Botrule Toprule"> <p class="First">Study 1</p> </td>      <td class="Botrule Toprule"> <p class="First">ABILIFY MAINTENA (400 to 300 mg)</p> <p>Placebo</p> </td>      <td class="Botrule Toprule"> <p class="First">102.4 (11.4)<br /> </p> <p>103.4 (11.1)</p> </td>      <td class="Botrule Toprule"> <p class="First">-26.8 (1.6)<br /> </p> <p>-11.7 (1.6)</p> </td>      <td class="Botrule Toprule" valign="middle"> <p class="First">-15.1 (-19.4, -10.8)</p> <p> <br />--</p> </td>      </tr>      <tr class="Last">       <td class="Toprule" colspan="5"> <p class="First">SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: unadjusted confidence interval.</p> <p> <span class="Bold"><span class="Sup">a</span></span> Difference (drug minus placebo) in least-squares mean change from baseline. </p> <p>The change in PANSS total score by week is shown in Figure 24. ABILIFY MAINTENA also showed improvement in symptoms represented by CGI-S score mean change from baseline to week 10. The results of exploratory subgroup analyses by gender, race, age, ethnicity, and BMI were similar to the results of the overall population. </p> <p> <span class="Bold">Figure 24: Weekly PANSS Total Score-Change in the 12-Week, Placebo-Controlled Study with ABILIFY MAINTENA</span> </p> <a name="id-1107506652"></a><img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%2024%2Ejpg" alt="Figure 24" /></td>      </tr>     </tbody>    </table>  </div>   <p> <span class="Bold">n = the number of patients remaining in the respective study arm at each time point</span> </p>   <p> <span class="Italics">Longer-Term Efficacy</span> </p>   <p>The efficacy of ABILIFY MAINTENA in maintaining symptomatic control in schizophrenia was established in a double-blind, placebo-controlled, randomized-withdrawal trial in adult patients (Study 2) who met DSM-IV-TR criteria for schizophrenia and who were being treated with at least one antipsychotic medication. Patients had at least a 3-year history of illness and a history of relapse or symptom exacerbation when not receiving antipsychotic treatment.</p>   <p>In addition to the PANSS and CGI-S, clinical ratings during this trial included the: </p>   <dl>    <dt>    1.   </dt>    <dd>    Clinical Global Impression-Improvement (CGI-I) scale, a scale of 1 (very much improved) to 7 (very much worse) based on the change from baseline in clinical condition and   </dd>    <dt>    2.   </dt>    <dd>    Clinical Global Impression-Severity of Suicide (CGI-SS) scale, which is comprised of 2 parts: Part 1 rates the severity of suicidal thoughts and behavior on a scale of 1 (not at all suicidal) to 5 (attempted suicide) based on the most severe level in the last 7 days from all information available to the rater and Part 2 rates the change from baseline in suicidal thoughts and behavior on a scale of 1 (very much improved) to 7 (very much worse).   </dd>   </dl>   <p>This trial included:</p>   <dl>    <dt>    1.   </dt>    <dd>    A 4 to 6&nbsp;week open-label, oral conversion phase for patients on antipsychotic medications other than aripiprazole. A total of 633 patients entered this phase.   </dd>    <dt>    2.   </dt>    <dd>    An open-label, oral aripiprazole stabilization phase (target dose of 10&nbsp;mg to 30&nbsp;mg once daily). A total of 710 patients entered this phase. Patients were 18 to 60&nbsp;years old (mean 40&nbsp;years) and 60% were male. The mean PANSS total score was 66 (range 33 to 124). The mean CGI-S score was 3.5 (mildly to moderately ill). Prior to the next phase, stabilization was required. Stabilization was defined as having all of the following for four consecutive weeks: an outpatient status, PANSS total score ≤80, CGI-S ≤4 (moderately ill), and CGI-SS score ≤2 (mildly suicidal) on Part 1 and ≤5 (minimally worsened) on Part 2; and a score of ≤4 on each of the following PANSS items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content.   </dd>    <dt>    3.   </dt>    <dd>    A minimum 12-week uncontrolled, single-blind ABILIFY MAINTENA stabilization phase (treatment with 400&nbsp;mg of ABILIFY MAINTENA given every 4&nbsp;weeks in conjunction with oral aripiprazole [10&nbsp;mg to 20&nbsp;mg/day] for the first 2&nbsp;weeks). The dose of ABILIFY MAINTENA may have been decreased to 300&nbsp;mg due to adverse reactions. A total of 576 patients entered this phase. The mean PANSS total score was 59 (range 30 to 80) and the mean CGI-S score was 3.2 (mildly ill). Prior to the next phase, stabilization was required (see above for the definition of stabilization) for 12 consecutive weeks.   </dd>    <dt>    4.   </dt>    <dd>    A double-blind, placebo-controlled randomized-withdrawal phase to observe for relapse (defined below). A total of 403 patients were randomized 2:1 to the same dose of ABILIFY MAINTENA they were receiving at the end of the stabilization phase, (400&nbsp;mg or 300&nbsp;mg administered once every 4&nbsp;weeks) or placebo. Patients had a mean PANSS total score of 55 (range 31 to 80) and a CGI-S score of 2.9 (mildly ill) at entry. The dose could be adjusted up and down or down and up within the range of 300 to 400&nbsp;mg on a one time basis.   </dd>   </dl>   <p>The primary efficacy endpoint was time from randomization to relapse. Relapse was defined as the first occurrence of one or more of the following criteria:</p>   <dl>    <dt>    •   </dt>    <dd>    CGI-I of ≥5 (minimally worse) and    </dd>   </dl>   <dl>    <dt>    1.   </dt>    <dd>    an increase on any of the following individual PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score &gt;4 with an absolute increase of ≥2 on that specific item since randomization or   </dd>    <dt>    2.   </dt>    <dd>    an increase on any of the following individual PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score &gt;4 and an absolute increase ≥4 on the combined four PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) since randomization    <br />    </dd>   </dl>   <dl>    <dt>    •   </dt>    <dd>    Hospitalization due to worsening of psychotic symptoms (including partial hospitalization), but excluding hospitalization for psychosocial reasons   </dd>    <dt>    •   </dt>    <dd>    CGI-SS of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2, or   </dd>    <dt>    •   </dt>    <dd>    Violent behavior resulting in clinically significant self-injury, injury to another person, or property damage.   </dd>   </dl>   <p>A pre-planned interim analysis demonstrated a statistically significantly longer time to relapse in patients randomized to the ABILIFY MAINTENA group compared to placebo-treated patients and the trial was subsequently terminated early because maintenance of efficacy was demonstrated. The final analysis demonstrated a statistically significantly longer time to relapse in patients randomized to the ABILIFY MAINTENA group than compared to placebo-treated patients. The Kaplan-Meier curves of the cumulative proportion of patients with relapse during the double-blind treatment phase for ABILIFY MAINTENA and placebo groups are shown in Figure 25.</p>   <p> <span class="Bold">Figure 25: Kaplan-Meier Estimation of Cumulative Proportion of Patients with Relapse<span class="Sup">1</span></span> </p>   <span class="Bold">    <div class="Figure">     <a name="id487988890"></a>    <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Figure%2025%2Ejpg" alt="Figure 25" />   </div> </span>   <p> <span class="Bold"><span class="Sup">1</span>This figure is based on a total of 80 relapse events</span> </p>   <p>The key secondary efficacy endpoint, percentage of subjects meeting the relapse criteria, was statistically significantly lower in patients randomized to the ABILIFY MAINTENA group (10%) than in the placebo group (40%).</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">17 PATIENT COUNSELING INFORMATION</a> <div class="Section toggle-content closed" data-sectioncode="34076-0">   <a name="S17"></a>  <a name="section-15"></a>   <p></p>    <p class="First">Advise the patient to read the FDA-approved patient labeling (<a href="#ID_f2710a2d-8b33-4cae-a3fb-af08023cf23a">Medication Guide</a>)<span class="Bold"></span> </p>   <p> <span class="Bold">Neuroleptic Malignant Syndrome </span> </p>   <p>Counsel patients and caregivers that a potentially fatal symptom complex sometimes referred to as NMS has been reported in association with administration of antipsychotic drugs. Signs and symptoms of NMS include hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia) <span class="Italics">[see </span><span class="Italics"><a href="#S5.3">WARNINGS AND PRECAUTIONS (5.3)</a></span><span class="Italics">]</span>.</p>   <p> <span class="Bold">Tardive Dyskinesia</span> </p>   <p>Advise patients that abnormal involuntary movements have been associated with the administration of antipsychotic drugs. Counsel patients to notify their physician if they notice any movements which they cannot control in their face, tongue, or other body part <span class="Italics">[see </span><span class="Italics"><a href="#S5.4">WARNINGS AND PRECAUTIONS (5.4)</a></span><span class="Italics">]</span>.</p>   <p> <span class="Bold">Interference with Cognitive and Motor Performance</span> </p>   <p>Because ABILIFY MAINTENA may have the potential to impair judgment, thinking, or motor skills, instruct patients to be cautious about operating hazardous machinery, including automobiles, until they are reasonably certain that ABILIFY MAINTENA therapy does not affect them adversely <span class="Italics">[see </span><span class="Italics"><a href="#S5.9">WARNINGS AND PRECAUTIONS (5.9)</a></span><span class="Italics">]</span>.</p>   <p> <span class="Bold">Heat Exposure and Dehydration</span> </p>   <p>Advise patients regarding appropriate care in avoiding overheating and dehydration <span class="Italics">[see </span><span class="Italics"><a href="#S5.10">WARNINGS AND PRECAUTIONS (5.10)</a></span><span class="Italics">].</span> </p>   <p> <span class="Bold">Concomitant Medication</span> </p>   <p>Advise patients to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, since there is a potential for interactions <span class="Italics">[see </span><span class="Italics"><a href="#S7">DRUG INTERACTIONS (7)</a></span><span class="Italics">]</span>.</p>   <p> <span class="Bold">Nursing</span> </p>   <p>Advise patients that breastfeeding is not recommended with ABILIFY MAINTENA treatment because of the potential for serious adverse reactions in a nursing infant <span class="Italics">[see </span><span class="Italics"><a href="#_8_USE_IN">USE IN SPECIFIC POPULATIONS (8.3)</a></span><span class="Italics">]</span>.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">SPL UNCLASSIFIED SECTION</a> <div class="Section toggle-content closed" data-sectioncode="42229-5">   <a name="ID_33aadd13-3ca9-4b83-918d-462bcd76c74e"></a>  <a name="section-16"></a>   <p></p>   <p class="First">Distributed and marketed by Otsuka America Pharmaceutical, Inc., Rockville, MD 20850 USA</p>   <p>Marketed by Lundbeck, Deerfield, IL 60015 USA</p>   <p>ABILIFY MAINTENA is a trademark of Otsuka Pharmaceutical Company.</p>   <p>09US14L-1029&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12/2014</p>   <p>&copy; 2014, Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">MEDICATION GUIDE</a> <div class="Section toggle-content closed" data-sectioncode="42231-1">   <a name="ID_f2710a2d-8b33-4cae-a3fb-af08023cf23a"></a>  <a name="section-17"></a>   <p></p>    <p class="First"> <span class="Bold">ABILIFY MAINTENA<span class="Sup">&reg;</span> (</span>a-BIL-i-fy main-TEN-a<span class="Bold">)</span> </p>   <p> <span class="Bold">(aripiprazole)</span> <br /> <span class="Bold">for extended-release injectable suspension, for intramuscular use</span> </p>   <p>Read this Medication Guide before you receive your first injection of ABILIFY MAINTENA and before each injection. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.</p>   <p> <span class="Bold">What is the most important information I should know about ABILIFY MAINTENA?</span> </p>   <p> <span class="Bold">ABILIFY MAINTENA may cause serious side effects, including:</span> </p>   <dl>    <dt>    •   </dt>    <dd>     <span class="Bold">Increased risk of death in elderly people with dementia-related psychosis.</span> ABILIFY MAINTENA is not for the treatment of people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia).   </dd>    <dt>    •   </dt>    <dd>     <span class="Bold">Neuroleptic malignant syndrome (NMS) a serious condition that can lead to death.</span> Tell your healthcare provider right away if you have some or all of the following symptoms of NMS:     <dl>      <dt>      -     </dt>      <dd>      high fever     </dd>      <dt>      -     </dt>      <dd>      stiff muscles     </dd>      <dt>      -     </dt>      <dd>      confusion     </dd>      <dt>      -     </dt>      <dd>      sweating     </dd>      <dt>      -     </dt>      <dd>      changes in pulse, heart rate, and blood pressure     </dd>     </dl>    </dd>   </dl>   <p> <span class="Bold">Call your healthcare provider right away if you have any of these symptoms.</span> </p>   <p> <span class="Bold">What is ABILIFY MAINTENA?</span> </p>   <p>ABILIFY MAINTENA is a prescription medicine used to treat schizophrenia.</p>   <p>It is not known if ABILIFY MAINTENA is safe and effective in children under 18&nbsp;years of age.</p>   <p> <span class="Bold">Who should not receive ABILIFY MAINTENA?</span> </p>   <p> <span class="Bold">Do not receive ABILIFY MAINTENA if you</span> are allergic to aripiprazole or any of the ingredients in ABILIFY MAINTENA. See the end of this leaflet for a complete list of ingredients in ABILIFY MAINTENA.</p>   <p> <span class="Bold">What should I tell my healthcare provider before receiving ABILIFY MAINTENA?</span> </p>   <p>Before you receive ABILIFY MAINTENA, tell your healthcare provider if you:</p>   <dl>    <dt>    •   </dt>    <dd>    have never taken ABILIFY (aripiprazole) before   </dd>    <dt>    •   </dt>    <dd>    have diabetes or high blood sugar or a family history of diabetes or high blood sugar. Your healthcare provider should check your blood sugar before you start receiving ABILIFY MAINTENA and during your treatment.   </dd>    <dt>    •   </dt>    <dd>    have or had seizures (convulsions)   </dd>    <dt>    •   </dt>    <dd>    have or had low or high blood pressure   </dd>    <dt>    •   </dt>    <dd>    have or had heart problems or a stroke   </dd>    <dt>    •   </dt>    <dd>    have or had a low white blood cell count   </dd>    <dt>    •   </dt>    <dd>    have any other medical problems including problems that may affect you receiving an injection in your buttocks   </dd>    <dt>    •   </dt>    <dd>    are pregnant or plan to become pregnant. It is not known if ABILIFY MAINTENA will harm your unborn baby.   </dd>    <dt>    •   </dt>    <dd>    are breastfeeding or plan to breastfeed. ABILIFY MAINTENA can pass into your milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you receive ABILIFY MAINTENA.   </dd>   </dl>   <p> <span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription medicines, non-prescription medicines, vitamins, and herbal supplements.</p>   <p>ABILIFY MAINTENA and other medicines may affect each other causing possible serious side effects. ABILIFY MAINTENA may affect the way other medicines work, and other medicines may affect how ABILIFY MAINTENA works.</p>   <p>Your healthcare provider can tell you if it is safe to take ABILIFY MAINTENA with your other medicines. Do not start or stop any medicines while taking ABILIFY MAINTENA without talking to your healthcare provider first.</p>   <p>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</p>   <p> <span class="Bold">How should I receive ABILIFY MAINTENA?</span> </p>   <dl>    <dt>    •   </dt>    <dd>    ABILIFY MAINTENA is an injection given in your buttock by your healthcare provider 1 time a month. You may feel a little pain in your buttock during your injection.   </dd>    <dt>    •   </dt>    <dd>    After your first injection of ABILIFY MAINTENA you should continue your current antipsychotic medicine for 2&nbsp;weeks.   </dd>    <dt>    •   </dt>    <dd>    You should not miss a dose of ABILIFY MAINTENA. If you miss a dose for some reason, call your healthcare provider right away to discuss what you should do next.   </dd>   </dl>   <p> <span class="Bold">What should I avoid while receiving ABILIFY MAINTENA?</span> </p>   <dl>    <dt>    a)   </dt>    <dd>    Do not drive, operate machinery, or do other dangerous activities until you know how ABILIFY MAINTENA affects you. ABILIFY MAINTENA may make you feel drowsy.   </dd>    <dt>    b)   </dt>    <dd>    Do not drink alcohol while you receive ABILIFY MAINTENA.   </dd>    <dt>    c)   </dt>    <dd>    Do not become too hot or dehydrated while you receive ABILIFY MAINTENA.     <dl>      <dt>      -     </dt>      <dd>      Do not exercise too much.     </dd>      <dt>      -     </dt>      <dd>      In hot weather, stay inside in a cool place if possible.     </dd>      <dt>      -     </dt>      <dd>      Stay out of the sun.     </dd>      <dt>      -     </dt>      <dd>      Do not wear too much clothing or heavy clothing.     </dd>      <dt>      -     </dt>      <dd>      Drink plenty of water.     </dd>     </dl>    </dd>   </dl>   <p> <span class="Bold">What are the possible side effects of ABILIFY MAINTENA?</span> </p>   <p> <span class="Bold">ABILIFY MAINTENA may cause serious side effects, including: </span> </p>   <dl>    <dt>    (a)   </dt>    <dd>     <span class="Bold">See &quot;What is the most important information I should know about ABILIFY MAINTENA?&quot;</span>    </dd>    <dt>    (b)   </dt>    <dd>     <span class="Bold">Uncontrolled body movements (tardive dyskinesia). </span>ABILIFY MAINTENA may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop receiving ABILIFY MAINTENA. Tardive dyskinesia may also start after you stop receiving ABILIFY MAINTENA.   </dd>    <dt>    (c)   </dt>    <dd>     <span class="Bold">Problems with your metabolism such as:</span>     <dl>      <dt>      a.     </dt>      <dd>       <span class="Bold">High blood sugar (hyperglycemia):</span> Increases in blood sugar can happen in some people who take ABILIFY MAINTENA. Extremely high blood sugar can lead to coma or death. If you have diabetes or risk factors for diabetes (such as being overweight or a family history of diabetes), your healthcare provider should check your blood sugar before you start receiving ABILIFY MAINTENA and during your treatment.     </dd>     </dl>    </dd>   </dl>   <p> <span class="Bold">Call your healthcare provider if you have any of these symptoms of high blood sugar while receiving ABILIFY MAINTENA:</span> </p>   <dl>    <dt>    &nbsp;   </dt>    <dd>     <dl>      <dt>      -     </dt>      <dd>      feel very thirsty     </dd>      <dt>      -     </dt>      <dd>      need to urinate more than usual     </dd>      <dt>      -     </dt>      <dd>      feel very hungry     </dd>      <dt>      -     </dt>      <dd>      feel weak or tired     </dd>      <dt>      -     </dt>      <dd>      feel sick to your stomach     </dd>      <dt>      -     </dt>      <dd>      feel confused, or your breath smells fruity     </dd>     </dl>    </dd>   </dl>   <dl>    <dt>    (d)   </dt>    <dd>     <span class="Bold">Decreased blood pressure (orthostatic hypotension). </span>You may feel lightheaded or faint when you rise too quickly from a sitting or lying position.   </dd>    <dt>    (e)   </dt>    <dd>     <span class="Bold">Low white blood cell count</span>    </dd>    <dt>    (f)   </dt>    <dd>     <span class="Bold">Seizures (convulsions)</span>    </dd>    <dt>    (g)   </dt>    <dd>     <span class="Bold">Problems controlling your body temperature so that you feel too warm. See &quot;What should I avoid while receiving ABILIFY MAINTENA?&quot;</span>    </dd>    <dt>    (h)   </dt>    <dd>     <span class="Bold">Difficulty swallowing</span>    </dd>   </dl>   <p>The most common side effect of ABILIFY MAINTENA includes feeling like you need to move to stop unpleasant feelings in your legs (restless leg syndrome or akathisia).</p>   <p>Tell your healthcare provider if you have any side effect that bothers you or does not go away.</p>   <p>These are not all the possible side effects of ABILIFY MAINTENA. For more information, ask your healthcare provider or pharmacist.</p>   <p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>   <p> <span class="Bold">General information about the safe and effective use of ABILIFY MAINTENA</span> </p>   <p>This Medication Guide summarizes the most important information about ABILIFY MAINTENA. If you would like more information, talk with your healthcare provider.</p>   <p>You can ask your healthcare provider or pharmacist for information about ABILIFY MAINTENA. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about ABILIFY MAINTENA that is written for healthcare professionals.</p>   <p>For more information about ABILIFY MAINTENA, go to www.ABILIFYMAINTENA.com or call 1-800-441-6763.</p>   <p> <span class="Bold">What are the ingredients in ABILIFY MAINTENA?</span> </p>   <p>Active ingredient: aripiprazole monohydrate</p>   <p>Inactive ingredients: carboxymethyl cellulose sodium, mannitol, sodium phosphate monobasic monohydrate and sodium hydroxide</p>   <p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">SPL UNCLASSIFIED SECTION</a> <div class="Section toggle-content closed" data-sectioncode="42229-5">   <a name="ID_8a148e96-6195-4764-93ac-fbb38d14063a"></a>  <a name="section-18"></a>   <p></p>   <p class="First">ABILIFY MAINTENA is a trademark of Otsuka Pharmaceutical Company.</p>   <p>09US14L-1029C&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12/2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br />&copy; 2014, Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL - 300 mg Vial Label</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="ID_23514336-75b6-449c-a481-a8ede4e72b0b"></a>  <a name="section-19"></a>   <p></p>    <p class="First"> <span class="Bold">NDC 59148-018-70</span> </p>   <p> <span class="Bold">Rx only</span> </p>   <p> <span class="Bold">300 mg per vial</span> </p>   <p> <span class="Bold">Abilify Maintena</span>™ <span class="Bold">(aripiprazole) </span> <br /> <span class="Bold"> for extended release injectable suspension </span> <br /> <span class="Bold"> Single use only.</span> Sterile. Discard any unused portion.<br /> <span class="Bold">For gluteal intramuscular injection only. </span> <br /> <span class="Bold"> Usual Dosage: </span>See package insert. <br /> 09US12L-1004</p>   <p>Manufactured by: Otsuka Pharmaceutical Co., Ltd. <br /> Distributed and Marketed by: Otsuka America Pharmaceutical, Inc. <br /> Marketed by: Lundbeck</p>   <div class="Figure">    <a name="id2777"></a>   <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=300%20mg%20vial%20label%2Ejpg" alt="PRINCIPAL DISPLAY PANEL - 300 mg Vial Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL - 300 mg Vial Carton</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="ID_be78e939-be71-4c15-9f6a-cc7e21c0fe45"></a>  <a name="section-20"></a>   <p></p>    <p class="First"> <span class="Bold">300 mg per vial</span> </p>   <p> <span class="Bold">Abilify Maintena</span>™</p>   <p>(aripiprazole) for extended release injectable suspension</p>   <p>Store at 25 &ordm;C (77 &ordm;F), excursions permitted <br /> between 15 &ordm;C and 30 &ordm;C (59 &ordm;F to 86 &ordm;F) <br /> [see USP Controlled Room Temperature].</p>   <p>Reconstitute at room temperature.</p>   <p> <span class="Bold">READ INSTRUCTIONS PRIOR TO USE.</span> </p>   <p>Usual Dosage: Administer once monthly.</p>   <p>See package insert.</p>   <div class="Figure">    <a name="id2804"></a>   <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=300%20mg%20Vial%20Carton%2Ejpg" alt="PRINCIPAL DISPLAY PANEL - 300 mg Vial Carton" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL - 400 mg Vial Label</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="ID_ecefefb4-7449-4e1f-867a-5722793f6ab0"></a>  <a name="section-21"></a>   <p></p>    <p class="First"> <span class="Bold">NDC 59148-019-70</span> </p>   <p> <span class="Bold">Rx only</span> </p>   <p> <span class="Bold">400 mg per vial</span> </p>   <p> <span class="Bold">Abilify Maintena</span>™ <span class="Bold">(aripiprazole) </span> <br /> <span class="Bold"> for extended release injectable suspension </span> <br /> <span class="Bold"> Single use only.</span> Sterile. Discard any unused portion. <br /> <span class="Bold">For gluteal intramuscular injection only. </span> <br /> <span class="Bold"> Usual Dosage: </span>See package insert. <br /> 09US12L-1005</p>   <p>Manufactured by: Otsuka Pharmaceutical Co., Ltd. <br /> Distributed and Marketed by: Otsuka America Pharmaceutical, Inc. <br /> Marketed by: Lundbeck</p>   <div class="Figure">    <a name="id2836"></a>   <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=400%20mg%20Vial%20Label%2Ejpg" alt="PRINCIPAL DISPLAY PANEL - 400 mg Vial Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL - 400 mg Vial Carton</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="ID_8137a8c2-6cdd-4ca0-8177-93d2d98159cc"></a>  <a name="section-22"></a>   <p></p>    <p class="First"> <span class="Bold">400 mg per vial</span> </p>   <p> <span class="Bold">Abilify Maintena</span>™</p>   <p>(aripiprazole) for extended release injectable suspension</p>   <p>Store at 25 &ordm;C (77 &ordm;F), excursions permitted <br /> between 15 &ordm;C and 30 &ordm;C (59 &ordm;F to 86 &ordm;F) <br /> [see USP Controlled Room Temperature].</p>   <p>Reconstitute at room temperature.</p>   <p> <span class="Bold">READ INSTRUCTIONS PRIOR TO USE.</span> </p>   <p>Usual Dosage: Administer once monthly.</p>   <p>See package insert.</p>   <div class="Figure">    <a name="id2863"></a>   <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=400%20mg%20vial%20carton%2Ejpg" alt="PRINCIPAL DISPLAY PANEL - 400 mg Vial Carton" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL - 5mL Water Label</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="ID_31ff9b44-5b82-4620-bf8f-8ef075531df8"></a>  <a name="section-23"></a>   <p></p>    <p class="First"> <span class="Bold">NDC 59148-100-01</span> </p>   <p> <span class="Bold">5mL</span> </p>   <p> <span class="Bold">Sterile Water </span> <br /> <span class="Bold"> for Injection, USP</span> </p>   <p> <span class="Bold">For single use only.</span> </p>   <p> <span class="Bold">Discard unused portion.</span> </p>   <p>Store at 25 &deg;C (77 &deg;F), excursions <br /> permitted between 15 &deg;C and 30 &deg;C<br />(59 &deg;F to 86 &deg;F) [See USP].</p>   <p>09US12L-1008</p>   <p> <span class="Bold">Rx only</span> </p>   <div class="Figure">    <a name="id2894"></a>   <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=Sterile%20Water%20Label%2Ejpg" alt="PRINCIPAL DISPLAY PANEL - 5mL Water Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL - 300 mg Syringe Label</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="ID_0d2d18fd-f7b8-4a26-bc13-c1f5cd399754"></a>  <a name="section-24"></a>   <p></p>    <p class="First"> <span class="Bold">NDC 59148-045-80</span> </p>   <p> <span class="Bold">300 mg</span> </p>   <p> <span class="Bold">Abilify Maintena<span class="Sup">&reg;</span> <br />(aripiprazole)</span> </p>   <p> <span class="Bold">for extended release <br />injectable suspension<br />Single use only.</span> </p>   <p>Sterile. Discard any <br />unused portion.</p>   <p> <span class="Bold">For gluteal <br />intramuscular <br />injection only.</span> </p>   <p> <span class="Bold">Usual Dosage: <br /> </span>See package insert.</p>   <p>516574AA</p>   <p> <span class="Bold">Rx only</span> </p>   <p>Store below<br />30&deg;C [86&deg;F].<br />Protect from light.</p>   <p>Mfd. by:<br />Otsuka Pharmaceutical <br />Co., Ltd.</p>   <p>09US14L-1027</p>   <p>516574AA</p>   <div class="Figure">    <a name="id-404843860"></a>   <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=300%20mg%20Syringe%20Label%2Ejpg" alt="Abilify Maintena DCS 300mg Label" />  </div>   <p> <span class="Bold">PRINCIPAL DISPLAY PANEL - 300 mg Syringe Carton</span> </p>   <p> <span class="Bold">For gluteal intramuscular injection only</span> </p>   <p> <span class="Bold">NDC 59148-045-80</span> </p>   <p> <span class="Bold">Abilify Maintena</span><span class="Sup">&reg;</span> <br />(aripiprazole) for extended release injectable suspension</p>   <p> <span class="Bold">300 mg PER PRE-FILLED<br />DUAL CHAMBER SYRINGE</span> </p>   <p> <span class="Bold">Attention: Dispense an enclosed Medication Guide to each patient.</span> </p>   <p> <span class="Bold">Single use only.<br />Keep out of reach <br />of children.</span> </p>   <p> <span class="Bold">Rx Only</span> </p>   <div class="Figure">    <a name="id1970701942"></a>   <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=300%20mg%20Syringe%20Carton%20Label%2Ejpg" alt="300 mg Syringe Carton Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL - 400 mg Syringe Label</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="ID_9573a67b-13cd-49e7-b0ed-4cd68fb4d8ea"></a>  <a name="section-25"></a>   <p></p>    <p class="First"> <span class="Bold">NDC 59148-072-80</span> </p>   <p> <span class="Bold">400 mg</span> </p>   <p> <span class="Bold">Abilify Maintena<span class="Sup">&reg;</span> <br />(aripiprazole)</span> </p>   <p> <span class="Bold">for extended release <br />injectable suspension<br />Single use only.</span> </p>   <p>Sterile. Discard any <br />unused portion.</p>   <p> <span class="Bold">For gluteal <br />intramuscular <br />injection only.</span> </p>   <p> <span class="Bold">Usual Dosage: <br /> </span>See package insert.</p>   <p>516579AA</p>   <p> <span class="Bold">Rx only</span> </p>   <p>Store below<br />30&deg;C [86&deg;F].<br />Protect from light.</p>   <p>Mfd. by:<br />Otsuka Pharmaceutical <br />Co., Ltd.</p>   <p>09US14L-1028</p>   <p>516579AA</p>   <div class="Figure">    <a name="id-272328670"></a>   <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=400%20mg%20Syringe%20Label%2Ejpg" alt="400 mg Syringe Label" />  </div>   <p> <span class="Bold">PRINCIPAL DISPLAY PANEL - 400 mg Syringe Carton</span> </p>   <p> <span class="Bold">For gluteal intramuscular injection only</span> </p>   <p> <span class="Bold">NDC 59148-072-80</span> </p>   <p> <span class="Bold">Abilify Maintena</span><span class="Sup">&reg;</span> <br />(aripiprazole) for extended release injectable suspension</p>   <p> <span class="Bold">400 mg PER PRE-FILLED<br />DUAL CHAMBER SYRINGE</span> </p>   <p> <span class="Bold">Attention: Dispense an enclosed Medication Guide to each patient.</span> </p>   <p> <span class="Bold">Single use only.<br />Keep out of reach <br />of children.</span> </p>   <p> <span class="Bold">Rx Only</span> </p>   <div class="Figure">    <a name="id-1140106234"></a>   <img src="image.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6&name=400%20mg%20Syringe%20Carton%20Label%2Ejpg" alt="400 mg Syringe Carton Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">INGREDIENTS AND APPEARANCE</a> <div class="DataElementsTables toggle-content">   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>ABILIFY MAINTENA&nbsp; </strong> <br /> <span class="contentTableReg">aripiprazole kit</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:59148-018</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:59148-018-71</td>          <td class="formItem">1 in 1 CARTON; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Quantity of Parts</td>          </tr>          <tr>           <th class="formTitle" width="5" scope="col">Part&nbsp;#</th>          <th class="formTitle" scope="col">Package Quantity</th>          <th class="formTitle" scope="col">Total Product Quantity</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem" width="5"><strong>Part 1</strong></td>          <td class="formItem">1 VIAL, SINGLE-USE</td>          <td class="formItem">1.5&nbsp;mL</td>          </tr>          <tr class="formTableRow">           <td class="formItem" width="5"><strong>Part 2</strong></td>          <td class="formItem">1 VIAL, SINGLE-USE</td>          <td class="formItem">5&nbsp;mL</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table cellpadding="5" cellspacing="0" width="100%">         <tbody>         <tr>           <td class="contentTableTitle">Part 1 of 2</td>          </tr>          <tr>           <td class="contentTableTitle"><strong>ABILIFY MAINTENA&nbsp; </strong> <br /> <span class="contentTableReg">aripiprazole injection, suspension, extended release</span></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt"></tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">INTRAMUSCULAR</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>aripiprazole</strong> (UNII: 82VFR53I78) (aripiprazole - UNII:82VFR53I78)</td>          <td class="formItem">aripiprazole</td>          <td class="formItem">300&nbsp;mg &nbsp;in&nbsp;1.5&nbsp;mL</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>carboxymethylcellulose sodium</strong> (UNII: K679OBS311)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>mannitol</strong> (UNII: 3OWL53L36A)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>sodium phosphate, monobasic, monohydrate</strong> (UNII: 593YOG76RN)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>sodium hydroxide</strong> (UNII: 55X04QC32I)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem"></td>          <td class="formItem">1.5 mL in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA202971</td>          <td class="formItem">02/28/2013</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table cellpadding="5" cellspacing="0" width="100%">         <tbody>         <tr>           <td class="contentTableTitle">Part 2 of 2</td>          </tr>          <tr>           <td class="contentTableTitle"><strong>WATER&nbsp; </strong> <br /> <span class="contentTableReg">water liquid</span></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt"></tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">INTRAMUSCULAR</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>Water</strong> (UNII: 059QF0KO0R)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem"></td>          <td class="formItem">5 mL in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA202971</td>          <td class="formItem">02/28/2013</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA202971</td>          <td class="formItem">02/28/2013</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>ABILIFY MAINTENA&nbsp; </strong> <br /> <span class="contentTableReg">aripiprazole kit</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:59148-019</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:59148-019-71</td>          <td class="formItem">1 in 1 CARTON; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Quantity of Parts</td>          </tr>          <tr>           <th class="formTitle" width="5" scope="col">Part&nbsp;#</th>          <th class="formTitle" scope="col">Package Quantity</th>          <th class="formTitle" scope="col">Total Product Quantity</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem" width="5"><strong>Part 1</strong></td>          <td class="formItem">1 VIAL, SINGLE-USE</td>          <td class="formItem">1.9&nbsp;mL</td>          </tr>          <tr class="formTableRow">           <td class="formItem" width="5"><strong>Part 2</strong></td>          <td class="formItem">1 VIAL, SINGLE-USE</td>          <td class="formItem">5&nbsp;mL</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table cellpadding="5" cellspacing="0" width="100%">         <tbody>         <tr>           <td class="contentTableTitle">Part 1 of 2</td>          </tr>          <tr>           <td class="contentTableTitle"><strong>ABILIFY MAINTENA&nbsp; </strong> <br /> <span class="contentTableReg">aripiprazole injection, suspension, extended release</span></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt"></tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">INTRAMUSCULAR</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>aripiprazole</strong> (UNII: 82VFR53I78) (aripiprazole - UNII:82VFR53I78)</td>          <td class="formItem">aripiprazole</td>          <td class="formItem">400&nbsp;mg &nbsp;in&nbsp;1.9&nbsp;mL</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>carboxymethylcellulose sodium</strong> (UNII: K679OBS311)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>mannitol</strong> (UNII: 3OWL53L36A)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>sodium phosphate, monobasic, monohydrate</strong> (UNII: 593YOG76RN)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>sodium hydroxide</strong> (UNII: 55X04QC32I)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem"></td>          <td class="formItem">1.9 mL in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA202971</td>          <td class="formItem">02/28/2013</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table cellpadding="5" cellspacing="0" width="100%">         <tbody>         <tr>           <td class="contentTableTitle">Part 2 of 2</td>          </tr>          <tr>           <td class="contentTableTitle"><strong>WATER&nbsp; </strong> <br /> <span class="contentTableReg">water liquid</span></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt"></tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">INTRAMUSCULAR</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>Water</strong> (UNII: 059QF0KO0R)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem"></td>          <td class="formItem">5 mL in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA202971</td>          <td class="formItem">02/28/2013</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA202971</td>          <td class="formItem">02/28/2013</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>ABILIFY MAINTENA&nbsp; </strong> <br /> <span class="contentTableReg">aripiprazole kit</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:59148-045</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:59148-045-80</td>          <td class="formItem">1 in 1 CARTON; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Quantity of Parts</td>          </tr>          <tr>           <th class="formTitle" width="5" scope="col">Part&nbsp;#</th>          <th class="formTitle" scope="col">Package Quantity</th>          <th class="formTitle" scope="col">Total Product Quantity</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem" width="5"><strong>Part 1</strong></td>          <td class="formItem">1 SYRINGE</td>          <td class="formItem">1.5&nbsp;mL</td>          </tr>          <tr class="formTableRow">           <td class="formItem" width="5"><strong>Part 2</strong></td>          <td class="formItem">1 SYRINGE</td>          <td class="formItem">5&nbsp;mL</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table cellpadding="5" cellspacing="0" width="100%">         <tbody>         <tr>           <td class="contentTableTitle">Part 1 of 2</td>          </tr>          <tr>           <td class="contentTableTitle"><strong>ABILIFY MAINTENA&nbsp; </strong> <br /> <span class="contentTableReg">aripiprazole injection, suspension, extended release</span></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt"></tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">INTRAMUSCULAR</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>aripiprazole</strong> (UNII: 82VFR53I78) (aripiprazole - UNII:82VFR53I78)</td>          <td class="formItem">aripiprazole</td>          <td class="formItem">300&nbsp;mg &nbsp;in&nbsp;1.5&nbsp;mL</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>carboxymethylcellulose sodium</strong> (UNII: K679OBS311)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>mannitol</strong> (UNII: 3OWL53L36A)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>sodium phosphate, monobasic, monohydrate</strong> (UNII: 593YOG76RN)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>sodium hydroxide</strong> (UNII: 55X04QC32I)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem"></td>          <td class="formItem">1.5 mL in 1 SYRINGE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA202971</td>          <td class="formItem">10/08/2014</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table cellpadding="5" cellspacing="0" width="100%">         <tbody>         <tr>           <td class="contentTableTitle">Part 2 of 2</td>          </tr>          <tr>           <td class="contentTableTitle"><strong>WATER&nbsp; </strong> <br /> <span class="contentTableReg">water liquid</span></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt"></tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">INTRAMUSCULAR</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>Water</strong> (UNII: 059QF0KO0R)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem"></td>          <td class="formItem">5 mL in 1 SYRINGE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA202971</td>          <td class="formItem">10/08/2014</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA202971</td>          <td class="formItem">10/08/2014</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>ABILIFY MAINTENA&nbsp; </strong> <br /> <span class="contentTableReg">aripiprazole kit</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:59148-072</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:59148-072-80</td>          <td class="formItem">1 in 1 CARTON; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Quantity of Parts</td>          </tr>          <tr>           <th class="formTitle" width="5" scope="col">Part&nbsp;#</th>          <th class="formTitle" scope="col">Package Quantity</th>          <th class="formTitle" scope="col">Total Product Quantity</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem" width="5"><strong>Part 1</strong></td>          <td class="formItem">1 SYRINGE</td>          <td class="formItem">1.9&nbsp;mL</td>          </tr>          <tr class="formTableRow">           <td class="formItem" width="5"><strong>Part 2</strong></td>          <td class="formItem">1 SYRINGE</td>          <td class="formItem">5&nbsp;mL</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table cellpadding="5" cellspacing="0" width="100%">         <tbody>         <tr>           <td class="contentTableTitle">Part 1 of 2</td>          </tr>          <tr>           <td class="contentTableTitle"><strong>ABILIFY MAINTENA&nbsp; </strong> <br /> <span class="contentTableReg">aripiprazole injection, suspension, extended release</span></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt"></tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">INTRAMUSCULAR</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>aripiprazole</strong> (UNII: 82VFR53I78) (aripiprazole - UNII:82VFR53I78)</td>          <td class="formItem">aripiprazole</td>          <td class="formItem">400&nbsp;mg &nbsp;in&nbsp;1.9&nbsp;mL</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>carboxymethylcellulose sodium</strong> (UNII: K679OBS311)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>mannitol</strong> (UNII: 3OWL53L36A)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>sodium phosphate, monobasic, monohydrate</strong> (UNII: 593YOG76RN)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>sodium hydroxide</strong> (UNII: 55X04QC32I)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem"></td>          <td class="formItem">1.9 mL in 1 SYRINGE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA202971</td>          <td class="formItem">10/08/2014</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table cellpadding="5" cellspacing="0" width="100%">         <tbody>         <tr>           <td class="contentTableTitle">Part 2 of 2</td>          </tr>          <tr>           <td class="contentTableTitle"><strong>WATER&nbsp; </strong> <br /> <span class="contentTableReg">water liquid</span></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt"></tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">INTRAMUSCULAR</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>Water</strong> (UNII: 059QF0KO0R)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem"></td>          <td class="formItem">5 mL in 1 SYRINGE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA202971</td>          <td class="formItem">10/08/2014</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA202971</td>          <td class="formItem">10/08/2014</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>Otsuka America Pharmaceutical, Inc. (008314390) </td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">Otsuka Pharmaceutical Co. Ltd.</td>      <td class="formItem"></td>      <td class="formItem">695314294</td>      <td class="formItem">MANUFACTURE(59148-018, 59148-019, 59148-045, 59148-072)</td>      </tr>     </tbody>   </table>  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li>                                            </ul>                                        <div class="control-nav">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                        </div>                                    </div>                        </article>                       <div class="articlefooternav">                       <h2>Find additional resources</h2> <strong>(also available in the <a href="#leftmenu">left menu</a>)</strong>                                              <h3>Safety</h3>                       <p>                                                            <a href="#boxedwarning" target="_blank">Boxed Warnings</a>,                                                                                                                     <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>,                                 <a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a>,                                 <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22aripiprazole%22+%29" target="_blank">Presence in Breast Milk</a>                                                   </p>                       <h3>Related Resources</h3>                       <p>                                                                                          <a href="http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=aripiprazole" target="_blank">Medline Plus</a>,                                                       <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=aripiprazole" target="_blank">Clinical Trials</a>,                            <a href="#pubmed-menu" id="pubmed-bottom">PubMed</a>,                            <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=APRD00638&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                                  </p>                       <h3>More Info on this Drug</h3>                       <p>                            <a href="#modal-label-archives" class="modal-open">View Label Archives</a>,                             <a href="#modal-rx-norm" class="modal-open">RxNorm</a>,                             <a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a>                        </p>                    </div>                </div>                                <div class="divider"></div>            </div>        </div>        <!-- Label Archives Modal --><div class="mfp-hide modal" id="modal-label-archives">        <div class="modal-wrapper">        <header><h2>View Label Archives for this drug</h2></header>        <div class="top">        							    	    																																			    																	    	    	                             		       	                                                                                                           <h3 class="long-title">ABILIFY MAINTENA- aripiprazole   <br></h3>            <h4>Number of versions: 4</h4>        </div>        <div class="modal-content">                <table class="modal">                    <tbody><tr>                        <th>Published Date</th>                        <th>Version</th>                               <th>Files</th>                    </tr>                                        <tr>                        <td>Dec 19, 2014</td>                        <td>							                                8                             							(current)                         </td>                              <td>                        								                                                            <a class="view-link" href="dailymed/drugInfo.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" title="View this Label">view</a><span class="sep"> | </span>                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=160629">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Nov 6, 2014</td>                        <td>							                                7                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=156729">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Sep 27, 2013</td>                        <td>							                                4                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=120415">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Apr 5, 2013</td>                        <td>							                                1                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=104626">download</a>                                                    </td>                    </tr>                                    </tbody></table>        </div>        </div></div>        <!-- RxNorm Modal --><div class="mfp-hide modal" id="modal-rx-norm">        <div class="modal-wrapper">        <header><h2>RxNorm</h2></header>        <div class="top">            <h3 class="long-title">ABILIFY MAINTENA- aripiprazole   <br></h3>        </div>        <div class="modal-content">        							    	    																																			    																	    	    	                             		       	                                                                                               			                            <table class="modal">                    <tbody><tr>                        <th></th>                        <th>RxCUI</th>                               <th>RxNorm NAME</th>                        <th>RxTTY</th>                    </tr>                                                                        <tr>                                                                    <td>1</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1371191">1371191</a></td>                              <td>aripiprazole 200 MG/ML Injectable Suspension</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>2</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1371191">1371191</a></td>                              <td>aripiprazole 300 MG per 1.5 ML Extended Release Injectable Suspension</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>3</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1371191">1371191</a></td>                              <td>aripiprazole 400 MG per 2 ML Extended Release Injectable Suspension</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>4</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1371194">1371194</a></td>                              <td>aripiprazole 200 MG/ML Injectable Suspension [Abilify]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>5</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1371194">1371194</a></td>                              <td>Abilify 200 MG/ML Injectable Suspension</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>6</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1371194">1371194</a></td>                              <td>Abilify Maintena 300 MG per 1.5 ML Extended Release Injectable Suspension</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>7</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1371194">1371194</a></td>                              <td>Abilify Maintena 400 MG per 2 ML Extended Release Injectable Suspension</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>8</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1602163">1602163</a></td>                              <td>1.5 ML aripiprazole 200 MG/ML Prefilled Syringe</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>9</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1602163">1602163</a></td>                              <td>aripiprazole 300 MG extended release Prefilled Syringe</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>10</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1602163">1602163</a></td>                              <td>aripiprazole 300 MG per 1.5 ML extended release Prefilled Syringe</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>11</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1602171">1602171</a></td>                              <td>2 ML aripiprazole 200 MG/ML Prefilled Syringe</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>12</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1602171">1602171</a></td>                              <td>aripiprazole 400 MG extended release Prefilled Syringe</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>13</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1602171">1602171</a></td>                              <td>aripiprazole 400 MG per 2 ML extended release Prefilled Syringe</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>14</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1602604">1602604</a></td>                              <td>1.5 ML aripiprazole 200 MG/ML Prefilled Syringe [Abilify]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>15</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1602604">1602604</a></td>                              <td>1.5 ML Abilify 200 MG/ML Prefilled Syringe</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>16</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1602604">1602604</a></td>                              <td>1.5 ML Abilify Maintena 200 MG/ML Prefilled Syringe</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>17</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1602604">1602604</a></td>                              <td>Abilify Maintena 300 MG extended release Prefilled Syringe</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>18</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1602604">1602604</a></td>                              <td>Abilify Maintena 300 MG per 1.5 ML extended release Prefilled Syringe</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>19</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1602607">1602607</a></td>                              <td>2 ML aripiprazole 200 MG/ML Prefilled Syringe [Abilify]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>20</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1602607">1602607</a></td>                              <td>2 ML Abilify 200 MG/ML Prefilled Syringe</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>21</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1602607">1602607</a></td>                              <td>2 ML Abilify Maintena 200 MG/ML Prefilled Syringe</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>22</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1602607">1602607</a></td>                              <td>Abilify Maintena 400 MG extended release Prefilled Syringe</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>23</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1602607">1602607</a></td>                              <td>Abilify Maintena 400 MG per 2 ML extended release Prefilled Syringe</td>                        <td>SY</td>                    </tr>                   	                </tbody></table>                    </div>        </div></div><!-- Label RSS Modal --><div class="mfp-hide modal" id="modal-label-rss">        <header><h2>Get Label RSS Feed for this Drug</h2></header>        <div class="top">            <h3 class="long-title">ABILIFY MAINTENA- aripiprazole   <br></h3>        </div>        <div class="modal-content">            <h4>To receive this label RSS feed</h4>            <p>Copy the URL below and paste it into your RSS Reader application.			<p><a href="https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6" target="_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6</a></p>            <h4>To receive all DailyMed Updates for the last seven days</h4>            <p>Copy the URL below and paste it into your RSS Reader application.</p>            <p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target="_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>            <h4>What will I get with the DailyMed RSS feed?</h4>            <p>DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.</p>            <p>DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.</p>            <h4>How to discontinue the RSS feed</h4>            <p>If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader.</p>            <a href="dailymed/rss-updates.cfm" class="rss-icon"></a> <a href="dailymed/rss-updates.cfm">More about getting RSS News & Updates from DailyMed</a>        </div></div>    <!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div><div class="hide-on-mobile"></div>    <div class="mobilenav no-js">        <ul>            <li><a href="dailymed/index.cfm">Home</a></li>            <li>News                <ul>                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                    <li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>                </ul>            </li>            <li>Search                <ul>                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                    	                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>	                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                            <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                </ul>            </li>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                <li>NLM SPL Resources                    <ul>                        <li><a href="dailymed/spl-resources.cfm">Download Data</a>                            <ul>                                <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                            </ul>                        </li>                        <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                        <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                    </ul>                </li>                <li>Application Development Support                    <ul>                        <li><a href="dailymed/app-support.cfm">Resources</a>                            <ul>                                <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                            </ul>                        </li>                    </ul>                </li>                        <li><a href="dailymed/help.cfm">Help</a></li>                                </ul>    </div>    <footer class="mainFooter">        <div class="container">            <div class="three columns">             <div class="nihnlmlogoprint"><img src="/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>                <a href="/www.nlm.nih.gov/" class="logo" title="National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png" width="109" height="37" alt="National Library of Medicine | National Institutes of Health" title="National Library of Medicine | National Institutes of Health" /></a>            </div>                        <div id="share" class="thirteen columns">                <div class="footer-links">                    <ul class="primary">                        <li><a href="dailymed/about-dailymed.cfm" title="About DailyMed">About DailyMed</a><span>|</span></li>                        <li><a href="dailymed/contact-us.cfm" title="Contact Us">Contact Us</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/copyright.html" title="Copyright" target="_blank" rel="bookmark">Copyright</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/privacy.html" title="Privacy" target="_blank" rel="bookmark">Privacy</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/accessibility.html" title="Web Accessibility" target="_blank" rel="bookmark">Web Accessibility</a><span>|</span></li>                        <li><a href="/www.hon.ch/HONcode/Conduct.html?HONConduct393117" target="_blank" title="HONCode Certification">DailyMed is HONCode Certified</a></li>                    </ul>                    <ul class="secondary">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">National Institutes of Health</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">U.S. National Library of Medicine</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <ul class="secondary mobile">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">NIH</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">NLM</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <div class="social">                        Share                         <!-- AddThis Button BEGIN -->                        <noscript>: JavaScript needed for Sharing tools</noscript>                        <div class="addthis_toolbox addthis_default_style addthis_16x16_style">							                                                            	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AABILIFY%20MAINTENA%2D%20Aripiprazole%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Dee49f3b1%2D1650%2D47ff%2D9fb1%2Dea53fe0b92b6%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                            <a class="addthis_button_facebook"></a>                            <a class="addthis_button_twitter"></a>                            <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="width: 16px; height: 16px">                                <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span>                                <img style="width:17px; margin-top: -2px;" src="/dailymed/images/addthis-image.jpg" alt="Bookmark &amp; Share">                            </a>                        </div>                                                <!-- AddThis Button END -->                    </div>                                    </div>            </div>        </div>                <div class="divider"></div>    </footer>    <div class="divider"></div></div><div class="to-top"></div><!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div> <div class="hide-on-mobile"></div><!-- START OF SmartSource Data Collector TAG --><!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. --><!-- Version: 9.4.0 --><!-- Tag Builder Version: 3.3  --><!-- Created: 1/25/2012 11:57:33 PM --><script type="text/javascript" src="/dailymed/scripts/webtrends.min.js"></script><!-- ----------------------------------------------------------------------------------- --><!-- Warning: The two script blocks below must remain inline. Moving them to an external --><!-- JavaScript include file can cause serious problems with cross-domain tracking.      --><!-- ----------------------------------------------------------------------------------- --><script type="text/javascript">//<![CDATA[var _tag=new WebTrends();_tag.dcsGetId();//]]></script><script type="text/javascript">//<![CDATA[_tag.dcsCustom=function(){// Add custom parameters here.//_tag.DCSext.param_name=param_value;_tag.DCSext.dcsid=_tag.dcsid}_tag.trackAllEvents=true;_tag.dcsCollect();//]]></script><noscript><div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src="//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"/></div></noscript><!-- END OF SmartSource Data Collector TAG --><script type="text/javascript">    setTimeout(function(){var a=document.createElement("script");    var b=document.getElementsByTagName("script")[0];    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);</script><script type="text/javascript">    function getParameterByName(name) {        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),            results = regex.exec(location.search);        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));    }    /* Tracking label type on search pages */    function CE_READY() {        if(!getParameterByName('labeltype')){           CE2.set(1, "No Label Type");        }        else{            var labeltype = getParameterByName('labeltype');            if(labeltype == 'all'){                CE2.set(1, "All");            }            else if(labeltype == 'human'){                CE2.set(1, "Human");            }            else if(labeltype == 'animal'){                CE2.set(1, "Animal");            }            else{                CE2.set(1, "Unknown");            }        }    }</script>                    <!-- DAP Universal Analytics -->    <script language="javascript" id="_fed_an_ua_tag" src="/dailymed/scripts/Universal-Federated-Analytics-Min.2.0.js?agency=HHS&subagency=NIH&enhlink=true&dclink=true"></script>    <script src="/dailymed/scripts/preview-text.min.js"></script></body></html>    